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The glycosylation profiles of biopharmaceuticals have a major impact on the 
bioactivity, bioavailability, biocompatibility and biosafety of the therapeutic. As 
modulation of the glycosylation profile can enhance or attenuate therapeutic properties of 
the drug, methods towards control of glycosylation therefore are of interest to the 
research, clinical and industrial communities. This work embarks on a multipronged 
approach towards achieving uniform, consistent and specified protein glycosylation 
through development of analytical methodologies to monitor attributes of glycosylation 
(Chapters 2-4), and by construction of a cell-free bioreactor for In-Vitro Glyco-
Engineering (Chapter 5). 
In objective (1) development of state-of-the-art analytical technologies 
demonstrated how Chinese Hamster Ovary (CHO) cells, subjected to high-flux substrates 
and cellular and protein engineering strategies, can be manipulated towards achieving 
control over the protein glycosylation pathway in mammalian cells. HPLC-based 
methods were employed to determine: amino acid composition, glycosylation patterns, 
nucleotide sugar distributions and titer. Modulation of the feed was shown to increase 
nucleotide sugars, specifically CMP-Neu5Ac, resulting in increased sialylation of 
proteins.  This detailed representation facilitated fundamental insight into the physiology 
of cellular responses, by synergizing how the glycosylation profile is inextricably coupled 
to substrate availability, enzyme activities and cellular metabolism, thereby revealing the 
interplay of the glycosylation processes at the systems level.  
In objective (2) implementation of a novel, transformative and scalable 
biofabrication process applying In-Vitro Glyco-Engineering of glycoproteins to produce 
 iii 
structurally well-defined, homogeneous glycans. This chemo-enzymatic approach utilizes 
Endoglycosidase-H covalently coupled to a solid phase support of silicon nanowires to 
deglycosylate proteins.  Select model glycoproteins: RNaseB, alpha-amlyase and IgG, 
showed the flexibility of the process towards different classes of biomolecules.  
These efforts will lead to higher productivity, increased product homogeneity and 
greater therapeutic efficacy. Ultimately, to enable the cost effective and routine 
production of biopharmaceuticals to facilitate increased patient affordability and larger 
profit margins. 
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It seems that the human mind has first to construct forms independently, before we can 
find them in things. Kepler’s marvelous achievement is a particularly fine example of the 
truth that knowledge cannot spring from experience alone, but only from the comparison 
of the inventions of the intellect with observed fact. 
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Chapter 1: Introduction 
1.1.Biopharmaceuticals, Antibodies and Glycosylation  
 The past century has seen countless scientific advances that have reshaped the 
fields of biochemistry and molecular biology.  These sophisticated and groundbreaking 
scientific achievements gave rise to the biopharmaceuticals industry.  In contrast to 
conventional pharmaceuticals that are produced by chemical synthesis, 
biopharmaceuticals are produced biologically, through recombinant or non-recombinant 
cell-culture expression systems where manufacturing process conditions dictate the 
product quality.  Biopharmaceuticals currently consist of vaccines, blood, blood 
components, allergenics, gene therapies, tissues, therapeutic proteins, and 
somatic/live cells.   Biopharmaceuticals are composed of sugars, proteins, or nucleic 
acids or complex combinations of these substances, or may be living cells or tissues. 
Additionally, they (or their precursors or components) are isolated from living sources, 
e.g. human, animal, plant, fungal, or microbial, their derivatives, and products of which 
they are components (e.g., conjugates).  Their inherent biological origin endows 
biopharmaceuticals with greater efficacy, efficiency and selectivity when compared to 
conventional pharmaceuticals. The biopharmaceuticals market can be segmented into 
oncology, inflammatory and infectious diseases, autoimmune disorders, metabolic 
disorders, hormonal disorders, disease prevention, cardiovascular diseases, neurological 
diseases and other diseases (Mordor Intelligence, 2017). Among these, oncology happens 
to be the largest segment with 30.5% share in the year 2015 (Mordor Intelligence, 2017).  
The scope of thesis shall encompass therapeutic proteins, i.e. immunoglobulin G1 (IgG1) 
monoclonal antibodies (mAbs).  
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 Biopharmaceuticals represent the major source of total company revenue for 
several major pharmaceutical companies, with the annual global biopharmaceuticals 
market increasing from $94 billion in 2007 to $177 billion in 2015 (Mordor Intelligence, 
2017). Amongst biopharmaceutical products, antibody based technologies are the largest 
market segment, comprising 37% of biopharmaceutical products in the year 2015 
(Mordor Intelligence, 2017).  Antibodies are over twenty of the fifty highest selling 
biopharmaceutical products in 2017 (EvaluatePharma, 2017) containing asparagine-
linked (N-linked) complex carbohydrates (glycans) at residue Asn297, thus rendering 
glycosylation a highly prevalent and impactful post-translational modification.  Along 
with a higher approval rate than other biopharmaceutical products, global sales of mAb 
products have grown faster than other biopharmaceuticals (Ecker, 2015).  Corresponding 
to the increasing sales of mAb products, there has been an increase in the total quantities 
produced annually to meet market demand, as 10 metric tons of were produced in 2013 
(Ecker, 2015).  The demand for mAbs has resulted in a significant amount of global 
biomanufacturing capacity devoted to their production as well as to significant 
improvements in methods and approaches to monoclonal antibody manufacturing process 
design and optimization (Ecker, 2015).  See Figure 1 for a schematic representation of the 




Figure 1. Schematic representation of the human IgG structure and glycan composition. 
(A) IgG structure. The IgG protein is comprised of two heavy chains (black outline) and 
two light chains (blue outline). Each IgG heavy chain has the variable region (VH) and 
the constant region containing three domains (Cγ1-3). The line between Cγ1 and Cγ2 
represents the hinge region. Each light chain has variable (VL) and constant lengths (CL). 
IgG molecule can be divided into antigen-binding fragment (Fab; empty ovals) and 
fragment crystallizable region (Fc; pink ovals). The red dot represents N-linked glycans 
of complex-type. (B) Composition of complex-type N-linked glycan on IgG. The glycan 
has a biantennary heptasaccharide core (solid line and in the gray block) and variable 
extensions (dash line). Abbreviations: F, fucose; N, GlcNAc; M, mannose; G, galactose; 
S, sialic acid. The enzymes, glycosyltransferases (left arrow) and glycosidases (right 
arrow), responsible for the addition or removal of the specific sugar are placed directly 
underneath of the sugar linkage. (C) Design of glycan composition on IgG Fc for 
potential antibody therapeutics. This figure was adapted from (Shade, 2013). 
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Glycosylation is responsible for considerable variation in product quality as 
current production systems are subject to batch-to-batch variability.  As the glycosylation 
profiles of biopharmaceuticals have a major impact on the bioactivity, bioavailability, 
biocompatilibility and biosafety of the drug (Del Val, 2013), they are deemed 
glycosylation-associated critical quality attributes (glcCQAs) that require control 
throughout the biopharmaceutical production campaign (Del Val, 2010).  In IgGs, 
afucosylation and galactosylation play important roles in the antibody-dependent cell-
mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), two 
important mechanisms for mAbs to mediate the immune function of killing target cells 
(Sha, 2016).  Fucose levels have been shown to have an inverse relationship with the 
degree of antibody-dependent cell-mediated cytotoxicity, and high mannose levels have 
been implicated in potentially increasing immunogenicity and contributing to less 
favorable pharmacokinetic profiles (Hossler, 2017).  The sialic acid content partially 
determines the mAb anti-inflammatory activity (Sha, 2016).  Indeed, as modulation of the 
glycosylation profile can enhance or attenuate therapeutic properties of the drug, methods 
towards control of glycosylation therefore are of interest to the research, clinical and 
industrial communities. However, the identification and control of critical process 
parameters that pose a risk to glcCQAs remain yet to be elucidated.   
Glycosylation is an important post-translational modification involved in a myriad 
of different cellular processes such as protein folding, cell growth and development, 
immunity, anti-coagulation, microbial pathogenesis, cancer metastasis (Neelamegham, 
2011), cell adhesion, molecular trafficking and clearance, receptor activation, signal 
transduction and endocytosis (Ohtsubo, 2006), and even during fertilization that initiates 
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life in multicellular organisms (Yarema, 2001).  The type(s) of glycan structures attached 
to the acceptor gives rise to altered properties of the acceptor molecule as changes in its 
polarity, conformation, solubility, and/or ligand-receptor interactions, resulting in the 
ability of the cell to precisely modulate the phenotype of many endogenous compounds. 
Absent and/or aberrant glycosylation pathways through alterations in glycosylation 
enzymes have been implicated in over 40 diseases in humans (Jaeken, 2013), such as 
various cancers, rheumatoid arthritis, autoimmune disease, diabetes as well as an 
increasing number of disease states related to child development (Ohtsubo, 2006; Varki, 
2009), these diseases are grouped under the classification “congenital defects of 
glycosylation” (Jaeken, 2013). 
Glycosylation is defined as the enzymatic process of adding sugars in glycosidic 
linkages to other molecules generating glyconjugates or complex carbohydrates 
(Cummings, 2005).  The term glycoconjugates includes glycoproteins, 
glycosylphosphoinositol (GPS) – anchored glycoproteins, glycolipids, 
glycosaminoglycans and proteoglycans, peptidoglycans, lipopolysaccharides, free 
oligosaccharides and polysaccharides (Cummings, 2005).  Glycans, which refers to the 
oligosaccharides, polysaccharides and carbohydrates, are considered to be one of the four 
major components of cells and have been described as one of the most abundant and 
structurally diverse nature’s biopolymers (Ohtsubo, 2006).  Cellulose, a polysaccharide 
comprising a linear chain of several hundred to over ten thousand β(1 → 4) linked D-
glucose units, is an important structural component of the primary cell walls of green 
plants and is the biggest contributor to the production of biomass on the planet 
(Behmüller, 2014). It is synthesized at the plasma membrane using UDP-Glc as glycosyl 
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donor, which represents the most prominent nucleotide sugar in plants and which is 
provided by either photosynthesis or from the cleavage of sucrose by sucrose synthase 
(Behmüller, 2014). Moreover, many trees contain high amounts of xylans, which are 
complex polysaccharides synthesized from UDP-xylose, and which account for up to 
30 % of the wood biomass (Behmüller, 2014).  In mammals, the glycome repertoire is 
vast and could potentially be larger than the proteome (Ohtsubo, 2006).  Additionally, a 
glycan may be modified with noncarbohydrate substituents, e.g., O-acetyl esters, O-
methyl ethers, amino acids, sulfates, and phosphoesters (Bar-Peled, 2011).  Despite this 
potentially enormous diversity, the mechanism of glycan synthesis is highly regulated 
and constricted, and only a few monosaccharides are used in the enzymatic process of 
mammalian glycosylation (Ohtsubo, 2006).  In general, 10 basic building blocks are used 
to build mammalian glycoconjugates (Cummings, 2004).  These include the 5-carbon 
pentoses (Xylose – Xyl and Fucose – Fuc), the 6-carbon hexoses (Glucose – Glc, 
Galactose – Gal, Mannose – Man), the 6-carbon hexosamines (N-acetylglucosamine – 
GlcNAc and N-acetylgalactosamine – GalNAc), the 6-carbon hexuronic acids 
(Glucuronic acid – GlcA and Iduronic acid – IdA), and the 9-carbon sialic acids (Sia, 
including N-acetylneuraminic acid – Neu5Ac and N-glycoylneruaminic acid – Neu5Gc) 






Figure 2: Structure and symbolic representations of common carbohydrates. This 
figure was adapted from (Dell, 2014). 
 
Glycosylation reactions occur by a sugar donor in the form of an activated, high-
energy nucleotide sugar transferring the sugar moiety to an acceptor such as a protein, 
lipid, or other bioorganic molecule.  Protein N- and O-glycosylation (the covalent 
attachment of carbohydrate sequences to the side-chains of asparagine and serine or 
threonine, respectively) is a phenomenon shared by all domains of life (Dell, 2014) 
throughout the entire phylogenetic spectrum, ranging from archaea to eubacteria to 
eukaryotes (Spiro, 2002).  However, the sequences of glycolytic enzymes differ between 
Archaea, Bacteria and Eukaryotes (Orellana, 2016).  Formation of glycosidic linkages 
and, thus the synthesis of conjugated oligosaccharide(s), requires the availability of the 
relevant nucleotide sugars (structures shown in Figure 4), which are initially synthesized 
from monosaccharides and nucleoside phosphates in the cytoplasm and nucleus of cells, 
with subsequent interconversions through phosphorylation, acetylation and epimerzation 
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reactions catalyzed by various families of enzymes including kinases, synthases and 
epimerases (Murrell, 2004), shown in Figure 3.  An exception is that CMP-Neu5Ac is 
generated in the nucleus and then transported into the golgi.  
 
 
Figure 3: Monosaccharide transport and metabolic processing reactions. Extracellular 
sugars are transported into cells (dashed lines), converted into additional varieties of 
monosaccharides by a series of phosphorylation, epimerization, and acetylation reactions, 
then condensed with CTP, GTP, or UTP to form nucleotide sugar donors (solid lines). 
The nucleotide sugar donors function as the “building blocks” for the production of 
complex carbohydrates; their biosynthesis generally occurs after they are transported into 









Figure 4: Chemical structures of some common nucleotide sugars. 
In contrast to protein isoforms, glycan structures are not directly encoded in the 
genome (Varki, 2009).  The vast glycan diversity exhibited for most proteins is 
generated as they traverse through the endoplasmic reticulum (ER) and various Golgi 
compartments due the stochastic nature of interactions between enzymes and 
oligosaccharide substrates and the variety of glycosyltransferase and glycosidase 
processing reactions that can act on any one glycan (Wang, 2017). Given its non-
template-driven nature, glycosylation heterogeneity arises both from variations in 
glycosylation site occupancy, i.e. macroheterogeneity, and in the diversity of the final 
glycan structures attached to glycoproteins, i.e. microheterogeneity, as glycans can 
emerge from the combinatorial action of exoglycosidases, chain extending and chain 
terminating glycosyltransferases emerging from the cellular secretory compartments 
(Wang, 2017).  Together, these reactions result in the construction of glycoproteins, 
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glycosphingolipids, proteoglycans and glycosylphosphatidylinositol-linked protein 
anchors (Neelamegham, 2011).  Schematic view of N-glycosylation processing is 
illustrated in Figure 5. 
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Figure 5: Schematic view of N-linked glycosylation processing in mammalian cells. 
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Glycosyltransferases utilize an activated donor sugar substrate containing a 
phosphate leaving group, most commonly as nucleoside diphosphate sugars (e.g., UDP 
Gal, GDP Man); however, nucleoside monophosphate sugars (e.g., CMP Neu5Ac), lipid 
phosphates (e.g., dolichol phosphate oligosaccharides), and unsubstituted 
phosphophrylated monosaccharides are also used (Lairson, 2008).  Nucleotide sugar-
dependent glycosyltransferases are often referred to as Leloir enzymes, in honor of Luis 
F. Leloir, who discovered the first sugar nucleotide (UDP-Glc) and was awarded the 
Nobel Prize in chemistry in 1970 for his enormous contributions to our understanding of 
glycoside biosynthesis and sugar metabolism. The acceptor substrates utilized by 
glycosyltransferases are most commonly other sugars but can also be a lipid, protein, 
nucleic acid, antibiotic, or another small molecule (Lairson, 2009).  For glycosyltransfer 
reactions to occur, sugar nucleotides generated in the metabolic reactions must be 
transported to the ER/Golgi by nucleotide sugar transporters (NSTs) (Neelamegham, 
2011), these processes are illustrated in Figure 6 for the glycosylation of a mAb in CHO 








Figure 6: mAb Fc N-linked glycosylation in the Golgi apparatus of mammalian cells. 
Linear representation of the enzymatic pathway of mAb Fc N-linked glycosylation in the 
Golgi apparatus of mammalian cells with a simplified illustration of the most important 
enzymatic reactions, transports mechanism and utilization of nucleotides and nucleotide 
sugars regarding N-linked glycosylation of monoclonal antibodies. This figure was 
adapted from (Villiger, 2016). 
 
Protein glycosylation can be either O-linked or N-linked.  N-linked glycosylation 
refers to glycan structure attached to the asparagine residue on proteins with an Asn-Xa-
Xb sequence of consensus (sequon) motif (Ohtsubo, 2006), where Xa is any amino acid 
except Proline (Varki, 2009).  O-linked glycosylation refers to glycans attached to serine 
or threonine residues (Ohtsubo, 2006).  In higher organisms, hundreds of genes partake in 
encoding the enzymes involved in glycosylation which can be divided into five major 
classes: glycosyltransferases, transglycosylation reverse glycosides, nucleotide sugar 
transporters, glycan donor transferases and lipid-linked donor transferases (Cummings, 
2004). The most common class of enzymes are the glycosyltransferases, which are 
responsible for sugar addition to the non-reducing (occasionally reducing) end of the 
glycan (Cummings, 2004).  Nascent polypeptides emerging from protein-conducting 
channels into the ER lumen are often cotranslationally modified with oligosaccharides at 
selected asparagine residues within the consensus sequence N-X-S/T (X ≠ P) (Harada, 
2013).  The native state stabilization and decreased activation barrier for folding 
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conferred by N-glycosylation enchances both the kinetics and the thermodynamics of 
protein folding (Hanson, 2009).  Furthermore, asparagine (N)-linked glycosylation of 
nascent polypeptides synthesized in the endoplasmic reticulum regulates the folding, 
degradation, and intracellular trafficking of the glycoproteins (Harada, 2013).  In 
mammals, N-glycosylation requires preassembly of the lipid-linked precursor, which is 
composed of three glucose (Glc), nine mannose (Man), and two N-acetylglucosamine 
(GlcNAc) residues linked to pyrophosphate (PP)-dolichol, Figure 7A. The 
monosaccharide units that compose the precursor are then donated either directly or 
indirectly from the nucleotide sugars UDP-Glc, GDP-Man, and UDP-GlcNAc, Figure 
7B.  Assembly of the precursor is a bipartite process that begins with the synthesis of the 
Man5GlcNAc2-PP-dolichol intermediate on the cytosolic side of the ER membrane, the 
intermediate is transferred with the aid of flippase into the ER lumen, where the 
oligosaccharide assembly pathway synthesizes Glc3Man9GlcNAc2-PP-dolichol (Harada, 
2013).  The oligosaccharide thus assembled is transferred to the Asn moiety of nascent 
polypeptides by oligosaccharyltransferase (OST) forming a GlcNAc–(β-N)–Asn bond.  
The discharged PP-dolichol moiety is then dephosphorylated to form 
monophosphorylated dolichol (P-dolichol), which can then serve as an acceptor substrate 
for the next cycle of oligosaccharide assembly (Harada, 2013).  
The normal N-glycosylation requires the completely-assembled Lipid-Linked 
Oligosaccahrides (LLO) as the optimal glycan donor substrate, however, genetic and 
environmental factors greatly influence the highly ordered biosynthesis and transfer of 
LLOs.  The intracellular pool of the nucleotide sugars UDP-GlcNAc, GDPMan, and 
UDP-Glc, which are essential precursors for the biosynthesis of LLOs, are regulated by 
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glucose metabolism (Harada, 2013).  Under a low-glucose environment induces arrest 
and the premature degradation of LLOs and release of phosphorylated monosaccharides 
from the LLO assembly, resulting in the synthesis of extensively truncated premature 
LLOs, thereby increasing risk of abnormal N-glycosylation (Harada, 2013).  Following, 
the transfer of the oligosaccharide onto the protein, this initiating event is followed by a 
“trimming” process, in which various glycosidases hydrolytically remove several 
monosaccharide units from the attached glycan to expose the pentasaccharide core 
(Khmelnitsky, 2004).  The resulting glycoprotein then undergoes further processing by a 
variety of glycosyltransferases that add back various sugars to the pentasaccharide to 
produce a wide diversity of oligosaccharide structures (Khmelnitsky, 2004).  The whole 
process occurs co-translationally, i.e., during protein synthesis but before the final protein 
molecule is formed and adopts its final conformation (Khmelnitsky, 2004).  N-glycan 
branching produced in the Golgi is dependent upon the sequential yet incomplete action 
of the Golgi α-mannosidases and N-acetylglucosaminyltransferases I, II, IV, and V 
(encoded by Mgat1, 2, 4, and 5), along with hexosamine pathway production of the 
substrate uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) (Grigorian, 2012).  
Additionally, the UDP-GlcNAc synthetic pathway is complex as it is a nexus of glucose, 
nucleotide, fatty acid and amino acid metabolic pathways.  Thus, the metabolic flow of 
glucose modulates the branching patterns of N-glycans via UDP-GlcNAc concentrations 
because many of the key GlcNAc transferases that determine the branching patterns have 






Figure 7: Model for N-glycoprotein biosynthesis in mammals. (A) Structure of fully 
assembled Glc3Man9GlcNAc2-PP-dolichol. (B) Model for the biosynthetic pathway and 
transfer of DLOs to proteins. Fruc-6-P, fructose 6-phosphate; Glc-1-P, glucose 1-
phosphate; Glc-6-P, glucose 6-phosphate; Man-1-P, mannose 1-phosphate; Man-6-P, 
mannose 6-phosphate. This figure was adapted from (Harada, 2013). 
 
Sialic acids are a family of nine carbon alpha-keto acids involved in a wide 
variety of biological functions in nature (Tanner, 2005).  These sugars are major 
determinants of cellular recognition and adhesion events, often found at the distal ends of 
cell surface glycoconjugates (Tanner, 2005) and secreted glycoproteins 
(Tangvoranuntakul, 2003).   In certain strains of pathogenic bacteria, they are found in 
capsular polysaccharides that mask the organism from the immune system by mimicking 
the exterior of a mammalian cell (Tanner, 2005).  Their negative charge at physiological 
pH, a result of their low acid-base disassociation constant, endows sialic acids with 
unique properties among other sugar moieties and has proven to be very important for 
several biological processes (Inoue, 2010).  Protein sialylation is the penultimate of a 
very complex process involving numerous glycosyltransferases, following specific sugars 
being trimmed in the Golgi, the terminal sialic acid is finally added by a sialyltransferase 
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in the Golgi (Li, 2012).  In nature, sialic acids are subject to a remarkable number of 
modifications, generating a diverse repertoire of more than 50 structurally distinct forms 
(Angata, 2001), but the most common ones are N-acetylnueraminic acid (Neu5Ac) and 
N-glycolylneuraminic acid (Neu5Gc) (Li, 2012).  Most mammals express both of these 
sialic acid structures, except humans only possess Neu5Ac (Kavaler, 2011).  Humans 
cannot synthesize Neu5Gc due to an inactivating mutation of a gene occurring in the 
human species around 3 million years ago (Tangvoranuntakul, 2003).  In mammalian 
organisms, CMP-Neu5Ac is generated in the nucleus in a multi-step process by the action 
of three enzymes, UDP-N-acetylglucosamine 2-epimerase, Sialic acid synthase and 
NeuNAc-9-phosphatase (Li, 2012).  The biosynthesis of the most common sialic acid, 
NeuNAc, begins with the formation of N-acetylmannosamine (ManNAc) from UDP-N-
acetylglucosamine (UDP-GlcNAc) (Angata, 2002).  In the following step, ManNAc is 
then phosphorylated to yield ManNAc 6-phosphate (ManNAc-6P) (Angata, 2002). Then 
condensation of either ManNAc or MacNAc-6P with phosphoenolpyruvate occurs to give 
NeuNAc or NeuNAc-9P (Angata, 2002, Li, 2012).  In mammals, NeuNAc-9P is then 
dephosphorylated to generate NeuNAc by NeuNAc-9-Phosphatase (Tanner, 2005).  
Dephosphorylation of Neu5Ac-9-P allows the Neu5Ac to then be transported into the 
nucleus. CMP-sialic acid synthase catalyzes the conjugation of Neu5Ac onto the 
activated nucleotide cytidine triphoshate forming CMP-Neu5Ac and diphosphate 
(Tanner, 2005).  CMP-sialic acid transporters then shuttle the CMP-Neu5Ac into the 





Figure 8: Metabolic details of sialoglycoconjugate biosynthesis. Upon production of the 
CMP-Neu5Ac “building blocks”, these compounds contribute a sialic acid residue during 
the assembly of sialoglycoconjugates. The final biosynthetic step is catalyzed by a suite 
of sialyltransferases (SIATnx)that work in parallel to provide α2,3-, α2,6-, or α2,8-linked 
sialoglycoconjugates.  This figure was adapted from (Murrell, 2004). 
 
CMP-sialic acid is the substrate for all sialyltransferases that incorporate these keto acid 
into glycoproteins and glycolipids (Tanner, 2005).  Increased attention has been given to 
sialic acids as they shown to be important in a wide range of cellular functions and 
human disease states.  Sialylation is associated with several physiological and 
pathological processes such as nervous system embryogenesis, cancer metastasis, 
immunological reguatlion and bacterial and viral infection (Li, 2012).  Given this 
importance, certain enzymes related to sialic acid metabolism, such as sialic acid 
synthases, sialyltransferases, sialidases and sialic acid modification enzymes, are all 
potential targets for drug development (Li, 2012).  While the activation and transfer 
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processes of sialic acids are conserved across bacteria to humans, the location of these 
enzymes differs between the two organisms (Li, 2012). The sialic acid content of proteins 
was found to be related to the proteins’ circulatory retention time (Fukuda et al. 1989; 
Goldwasser et al. 1974; Higuchi et al. 1992).  The proposed mechanism was that when 
exposed galactose residues of the glycan are recognized by the asialoglycoprotein 
receptor (ASPR), this induces binding of the protein and initiation of a protein 
degradation process (Morell et al. 1968).  Thus, glycoproteins with sialic acid can evade 
the capture of the ASPR.  Since then, the strategy of increasing the total sialic acid 
content of proteins was employed to prolong several biotherapeutics’ circulation retention 
time such as acetylcholinesterase (Chitlaru et al. 2002), butyrylcholinesterase (Schneider 
et al. 2014), tissue plasminogen activator (Weikert et al. 1999) and erythropoietin (Egrie 
et al. 2003).   
Modifying medium and feed, optimizing culture process, and engineering 
genetic elements of the cell are three major approaches for fine-tuning N-glycosylation 
patterns of recombinant proteins leading to the possibility of controlling protein N-
glycosylation in cell culture (Fan, 2015).  Modification of the medium and feed has the 
advantage of achieving successful N-glycosylation modulation in a relatively fast and 
easy process independent of cell line genetics (Fan, 2017).  It is therefore often favored 
to be applied in the later stage of industrial bioprocess development when a production 
cell line has already been developed (Fan, 2017).  Classical culture components such as 
glucose, galactose, amino acids, NH4
+, and many feed additives, such as manganese, 
sodium butyrate, and nucleotide and nucleotide sugar precursors, have been shown to 
be able to modulate protein N-glycosylation in cell culture (Fan, 2017).  Hills et. al 
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(2001), proposed that Fc N-glycan processing, specifically galactosylation and 
sialylation, can be improved by metabolic control of the level of the respective nucleotide 
sugar substrate in cells.   As similar studies utilizing other recombinant glycoproteins 
produced by animal cells in culture demonstrated that N-glycosylation can be altered 
through the addition of nucleotide sugar precursors to the cell culture medium (Hills, 
2001).  With respect to the control of N-glycan processing in animal cells in culture, the 
latter concept is based on the general hypothesis that addition of specific metabolic 
intermediates involved in nucleotide sugar biosynthesis to the culture medium will 
promote metabolic flux toward a specific nucleotide sugar (Hills, 2001).  Consequently, 
the altered transport and availability of that nucleotide sugar substrate within the Golgi 
lumen would promote specific alterations in nucleotide sugar availability and subsequent 
N-glycan processing (Hills, 2001).  Recently, Yin et. al (2017), have discovered a novel 
sugar analog, 1,3,4-O-Bu3-ManNAc, capable of enhancing sialic acid production and 
biotherapeutic sialylation in CHO cells.  This analog was used to stimulate sialic acid 
production discussed later in chapter 4.  The molecular structure and its incorporation 
into the metabolic pathway is shown in Figure 9. 
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Figure 9: (A) Sialic acid synthesis pathway; (B) structures of ManNAc and its 
analog. This figure was adapted from (Yin et. al, 2017) 
  
Chinese hamster ovary (CHO) cells have emerged as the predominant platform 
for the heterologous production of biotherapeutic proteins mainly due to their well 
characterized molecular biology, unparalleled adaptability, the ability to grow in both 
adherent and serum-free suspension cell cultures, long-term success in industrial scale 
production, and most importantly in their ability to generate appropriate post-
translational modifications most similar to that of humans (Fan, 2017).  Furthermore, 
studies in the late 1980’s revealed that human viral contaminations such as HIV, polio, 
herpes, and measles, do not replicate in CHO, thus outweighing the use of human cells as 
biological production hosts (Wiebe, 1989).  CHO cells are thus an ideal platform capable 
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of the biosynthetic complexity required to produce biopharmaceuticals.  Fed-batch CHO 
cell culture is the most commonly used process for IgG production in the 
biopharmaceutical industry (Templeton, 2013). Amino acid and carbohydrate 
composition, cell growth, metabolism, titer, and glycosylation patterns have always been 
the major concerns during upstream process optimization, especially media optimization 
(Fan, 2015).  Thus, being able to monitor these parameters would be of great asset to 
understand the impact of each towards concerted efforts to direct the glycosylation 
pattern.  However, the adaptability of the CHO line also has its drawbacks, as each 
production target requires the selection of clones that exhibit the necessary phenotypic 
properties, such as product quality/uniformity, doubling time and long term viability, 
under the used bioprocess conditions (Jadhav, 2013).  Even when an appropriate CHO 
production clone has been identified, phenotypic drift (i.e. changes in the previously 
selected characteristics) is not uncommon and remains a challenge (Jadhav, 2013).  
Glycosylation is subject to changes during fed-batch cultures by disturbing the complex 
interaction of multiple components including metal cofactors, nucleotides, nucleotide 
sugars and the acceptor sugars itself (Villiger, 2016).  Manipulation of these components 
using various cell culture supplementations is a cost- and time-effective way to modulate 
and fine-tune glycosylation, since the degree of glycosylation is mainly changed through 
a shift of intracellular compounds or glycosyltransferase activities while maintaining 
consistent process performance. Metal cofactors such as manganese have been applied to 
enhance the enzymatic activity leading to more processed glycan structures (Villiger, 
2016).  Supplementing cell culture media with glucosamine, galactose or N-
acetylmannosamine has been shown to increase the corresponding intracellular levels of 
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nucleotide sugars uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), uridine 
diphosphate galactose (UDP-Gal) or cytidine diphosphate N-acetylneuraminic acid 
(CMP-Neu5Ac), respectively (Villiger, 2016).  As nucleotides are precursors to 
nucleotide sugars, their nucleotide synthesis is an energy intensive process that uses 
multiple metabolic pathways across different cell compartments and several sources of 
carbon and nitrogen (Lane, 2015). These processes are regulated at the transcription level 
by a set of master transcription factors but also at the enzyme level by allosteric 
regulation and feedback inhibition, and at different stages of the cell cycle, during which 
these events are regulated at multiple levels (Lane, 2015).  The nucleotide pools play an 
ambivalent role in terms of glycosylation since they can either increase the concentration 
of nucleotide sugar donors or act as enzyme inhibitors in their (di)-phosphorylated forms 
inside the Golgi as shown in Figure 6 (Villiger, 2016).  Furthermore, combinations of 
different factors such as galactose, uridine and manganese have been found to have 
synergistic effects on N-linked glycosylation (Villiger, 2016). Refer to Table 1 for a 












Table 1: Comparison of effectiveness of reported nucleotide sugar feeding experiments.  




When culture medium and feed supplement medium are chosen, modification of 
these media can be done by addition of different amounts of feed additives or feed 
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additive combinations, including, but not limited to, glucose, glutamine, other amino 
acids, galactose, sodium butyrate, uridine, manganese, and other nucleotide sugar 
precursors (Fan, 2017).  In particular, extracellular and intracellular metabolic analysis is 
very commonly used in exploring metabolic bottlenecks in cell culture and provides 
guidance for further optimizing the medium and feed (Fan, 2017).  Towards this goal, 
development of a toolset to provide inputs to defining such acceptable criteria during the 
manufacturing campaign, through HPLC-based methods to determine the amino acid 
composition, glycosylation patterns, nucleotide sugar distributions and titer were 
established. 
Numerous factors influence cellular carbohydrate composition, and the 
combination of biochemical and metabolism-based approaches in conjunction with 
omic’s methods will accelerate efforts towards understanding glycosylation (Yarema, 
2001).  Integration of cellular engineering (through enzyme knockout/knock-ins), feeding 
strategies, detailed metabolic analysis, and glycan analysis may uncover the fundamental 
intricacies in cellular physiology. As the intracellular metabolism directly impacts 
glycosylation and biologic actively at scale, gaining knowledge on a systems level 
interaction network would provide insight into obtaining higher IgG titers and better 
control of glycosylation-related product qualities.  Furthermore, this systems biology 
approach may provide clues to enhance production capabilities by revealing rational 
strategies for cell line selection and process development.  Towards this goal a more in-
depth physiological understanding of cellular responses to particular process conditions 
and subsequent detailed glycoprotein characterization is presented with the aim of 
increasing the sialic acid content on mAbs through use of (Yin et. al, 2017) high-flux 
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ManNAc analog.  This work embarks on a multipronged approach towards achieving 
uniform, consistent and specified protein glycosylation through development of analytical 
methodologies to monitor glcCQAs (Chapters 2-4), and by construction of a cell-free 







































Chapter 2: N-Glycan Analysis using HILIC-FD 
2.1 Introduction 
 
The status of a protein’s glycosylation can reveal highly valuable diagnostic 
information.  For instance, glycomics studies may reveal disposition to diseases such as 
sialuria and the identification of protein glycans as biomarkers of life-threatening 
diseases such as cancer.  In the biopharmaceutical industry, glycan analysis is of 
paramount importance, as it has a profound impact on many properties of proteins that 
can alter the physicochemical properties of the therapeutic such as efficacy, safety and 
PK/PD profiles (Zhang, 2016). According to the International Conference on 
Harmonization (ICH) ICH Q5E, ICH Q6B, the FDA’s Guidance for Industry; the 
structure, content, and glycosylation sites should be investigated as thoroughly as 
possible.  However, the assessment of glycan structures is challenging due to the isomeric 
and branched nature of oligosaccharides (Cook, 2010).  Moreover, no method reported 
can determine the glycosylation site, glycan structure and abundance in a single run.  
Therefore, the use of complementary and orthogonal methods for appropriately assessing 
specific glycosylation attributes is required to ensure comprehensive and accurate 
coverage of glycosylation, thereby providing corroboratory information to clarify 
instances of inconclusive data.  High-performance liquid chromatography (HPLC), High 
pH Anion Exchange Chromatography-Pulsed Amperometric Detection (HPAEC-PAD), 
capillary electrophoresis (CE), mass spectrometry (MS), isoelectric focusing (IEF), and 
lectin-based microarray (Zhang, 2016), are typical methods employed to study glycan 
attributes, each with specific advantages and disadvantages, and are industry standards in 
glycan analysis (Cook, 2015).  Prior to separation and detection, glycans enzymatically or 
chemically released from the protein.  A drawback of this approach is that it captures a 
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protein’s global glycosylation pattern, as opposed to site-specific profiling, which results 
in an average determination of glycans present.  Following release, the complex mixture 
of oligosaccharides present then requires high-efficiency separation techniques prior to 
characterization, typically accomplished by mass spectrometry (MS). Detection by light 
absorption, i.e. Ultraviolet (UV) detection, cannot be used at this stage because glycans 
lack chromophores.  To circumvent this limitation, HPAEC-PAD combines a unique 
mode of separation with a selective detective strategy through oxidation of functional 
groups by specifically applied voltages on an electrode that is sensitive only to 
carbohydrates.  However, MS and HPAEC-PAD equipment is expensive, requires 
substantial maintenance, and highly-trained personnel to operate and interpret data.  The 
more commonly used approach is to label the glycans with a fluorescent molecule, 
followed by HPLC with fluorescence detection.  Among the fluorescent molecules that 
can be used for tagging carbohydrates, 2-aminobenzoic acid and 2-aminobenzamide (2-
AB), are the most commonly used when HPLC is the selected separation technique 
(Cook, 2016). The tagging protocol with 2-AB is relatively simple, results in negligible 
desialylation, and is quantitative (Cook, 2016).  Moreover, glycans and 2-AB are strongly 
bound through an amide bond, thus the tagged molecules have excellent stability (Cook, 
2016). 
Variations in the N-linked glycan profile (macro- and micro-heterogeneity) can 
occur during the mAb production process.  Studying the impact of various environmental 
factors and process conditions will increase understanding of the glycosylation machinery 
and provide the potential to control and target desired mAb glycoforms. Multiple cell 
culture conditions during upstream processing such as different feeding regimes, media 
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supplementation, as well as waste metabolite accumulation can affect glycosylation 
(Ivarsson, 2014).  Limiting glucose concentrations in fed-batch culture showed a 
reduction in terminal galactosylation for a chimeric heavy chain antibody (Ivarsson, 
2014).  Moreover, supplementation with manganese chloride, galactose and uridine can 
provide control over galactosylation during fed-batch cultivation (Ivarsson, 2014).  Aside 
from metabolic control, bioreactor process parameters such as pH, temperature, dissolved 
O2 and CO2 levels, and shear stress through agitation and sparging can lead to variability 
in the glycoform profile and thus, play an important role in manipulating and actively 
controlling the product quality (Ivarsson, 2014).  While the impact of process parameters 
on N-linked glycosylation has been summarized in literature (Butler, 2006; Hossler, 
2009), the effects shown are often incoherent and incomplete, and therefore do not allow 
general conclusions.  This is partly due to the fact that glycosylation is dependent on the 
3-dimensional structure of the protein, the enzyme repertoire of the host cell, the transit 
time in the Golgi and the availability of intracellular sugar-nucleotide donors (Butler, 
2006).   
IgG plays important roles in both innate and adaptive immunities, in which the 
state of glycosylation provides the capacity to regulate the intrinsic underlying IgG 
functions through glycan-dependent structural effects in the receptor-binding regions of 
the hinge/CH2 and CH2/CH3 domains (Jefferis, 2009).  These IgG glycoform 
conformational variants differentially interact with the FcγRs and other receptors 
variously expressed on immune cells and other cells throughout the body. Therefore, the 
absence or modification of Fc glycans can profoundly affect the therapeutic performance 
of mAbs by modulation or loss of intended functions, greater immunogenicity, and 
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unfavourable pharmacokinetic profiles (Jefferis, 2009). The glycans of IgG Fc are 
incomplete structures with varying amounts of branch N-acetylglucosamine and terminal 
galactose, and generally minimal sialylation (Jefferis, 2009).  Human IgG Fc N-glycans 
have a very high degree of core fucosylation and a low degree of bisecting N-
acetylglucosamine (Jefferis, 2009).  Immunoglobin G (IgG) with α-2,6 sialylation has 
been reported to have an impact on antibody-dependent cellular cytotoxicity and anti-
inflammatory efficacy (Chung, 2017).  Due to the inaccessibility of sialyltransferases for 
the heavy chain N-glycan site, production of antibodies with α-2,6 sialylation from CHO 
cells is challenging, since CHO cells exclusively possess α-2,3 sialyltransferases (Chung, 
2017).  Chung et. al demonstrated through combining mutations on the Fc regions to 
allow sialyltransferase accessibility in combination with overexpression of α-2,6 
sialyltransferase, IgGs were produced with significant levels of both α-2,6 and α-2,3 
sialylation as determined by MS. α-2,3 sialylation was disrupted by CRISPR/Cas9 
targeting the ST3GAL4 and ST3GAL6 genes (Chung, 2017). Resulting in α-2,3 linked 
sialic acids not detected on IgG produced from the α-2,3 sialyltransferase knockout-α-2,6 
sialyltransferase overexpression pools (Chung, 2017).  Glycoprofiling of IgG with four 
amino acid substitutions expressed from an α-2,3 sialyltransferase knockout-α-2,6 
sialyltransferase stable clones resulted in more than 77% sialylated glycans and more 
than 62% biantennary disialylated glycans as indicated by both MALDI-TOF and LC-
ESI-MS (Chung, 2017).  In this study, the N-glycans from three of the genetically 
engineering mAbs (Chung, 2017) were analyzed by HILIC-FD.  This chapter describes a 
complete workflow for the analysis of Immunoglobin G (IgG) protein N-glycans. The 
sample-preparation procedure, consisting of IgG purification, then release of the N-
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glycans by PNGase-F, followed by fluorescence labeling with 2-aminobenzamide (2-
AB), removal of excess label, and separation and detection by HILIC-FD.  Because 2-
AB-glycans are hydrophilic compounds, the HPLC separation technique most frequently 
chosen is hydrophilic interaction liquid chromatography (HILIC) with fluorescence 
detection. The results were shown to distinctive elution profiles in each antibody studied, 
thus verifying the effects of the applied protein and cellular engineering strategies.  To 
demonstrate the accuracy of the method the antibody samples were additionally analyzed 
by an orthogonal method, MALDI-ToF.  The consistency of the results between these 






























2.2 Methods & Materials 
 
2-Aminobenzoic Acid (2-AB, Sigma Aldrich) 
Dimethylsulfoxide (DMSO, Sigma Aldrich) 
Acetic Acid (Sigma Aldrich) 
Milli-Q H2O (house tap) 
Trifluoroacetic acid (TFA), Fisher #A116-05amp or equivalent 
Acetonitrile, HPLC grade, Fisher #BPA998-4 
1-Propanol: Fisher #A414-4 
Ammonium Hydroxide 21%, Fisher #A470-250 
Formic Acid, Proteochem #LC6201-10amps 
Hydrochloric Acid, Fisher #SA49 
Carbograph Column (3.0mL, Grace) 
MabSelect SuRe protein A resin (Sigma Aldrich) 
Waters Xbridge Amide column, 3.5 μm, 2.1 x 150 mm (# 186004861) 
Acetic acid (Fisher Scientific, Cat. # AC222140010) 
Dimethyl sulfoxide (DMSO) (Fisher Scientific, Cat. # AC397600010) 
2-Aminobenzamide (2-AB) (Sigma-Aldrich, Cat. # A89804) 
Sodium cyanoborohydride (NaBH3CN) (Sigma-Aldrich, Cat. # 156159) 
Maltotetraose (DP4) (Sigma-Aldrich, Cat. # 47877) 
PNGase F (Promega Corporation, Cat. # V4831) 
Tris-HCl (Sigma Aldrich) 
Glycine (Sigma Aldrich) 
Speedvac 
Agilent 1260 quaternary solvent delivery with FLD, PDA, and Column Oven 
 
2.2.1 IgG protein purification using Protein-A Agarose Beads 
1. Samples from cell culture are centrifuged at 4500 × g for 20 min.  
2. Filter the supernatant through a 0.22 μm low protein-binding filter. 
3. Then apply onto a MabSelect SuRe ProteinA column, into which 200 μL of MabSelect 
SuRe protein A resin slurry is packed.   
4. Equilibrate the column with 2 mL of 1× PBS.  
5. Load the filtered supernatant into the column and repeat for at least two times to ensure 
sufficient binding of IgG to the column.  
6. Wash the column with 4 mL of 1× PBS, perform twice.  
7 Elute IgG by 500 μL of 0.1 M citrate pH = 3.5. 
8. Neutralize the pH of eluate by adding 1 M Tris-HCl, pH 9.0.  
7. Separate the IgG from the beads by performing a centriguation step at 3000rpm for 5 
minutes. 
8. Collect the supernatant, as this contains the purified IgG, being careful not to disturb 
the pellet. 
9. Dialyze the IgG into an appropriate buffer for next steps, e.g. 10mM Ammonium 
Bicarbonate using Amicon Ultra flow filter unit with molecular weight cut-off (MWCO) 




2.2.2 Release of Glycans 
1. Release the N-Glycans by adding 1uL PNGase F (New England Biolabs) per 50µg 
protein.  
2. Incubate the reaction overnight in a 37°C incubator. 
3. Purify the released glycans using Extract-Clean SPE Carbograph columns (Grace). 
4. Add 3 mL of acetonitrile (100%) to carbograph cartridge.  
5. Add 3 mL of 1% TFA, repeat once.  
6. Load sample to Carbograph, allow sample solution penetration to cartridge by gravity.  
7. Re-load the flow-through to Carbograph for an additional time.  
8. Wash cartridge with 3 mL of 0.1% TFA, repeat four additional times.  
9. Wash cartridge with 3mL of 0.1% TFA in 10% acetonitrile.  
10. Elute sample with 400 μL of 0.1% TFA in 80% acetonitrile, repeat once.  
11. Dry sample solution in SpeedVac at 37°C. 
 
2.2.3 Prepartion of 2-AB Labeling Solution 
1. To make 400 µl 2-AB labeling solution, add 20 mg 2-aminobenzamide into 200 µl 
solvent (150 µl glacial acetic acid + 350 µl Dimethyl sulfoxide).  
2. Add 25 mg NaBH3CN into 200 µl solvent (as above).  
3. Combine equal volumes of both solutions.  
4. Total volume can be adjusted based on the amount of 2-AB ingredient weighted. 
CAUTION: NaBH3CN should be handled in a fume hood. Less toxic 2-picoline borane 
with same molar concentration can be used as alternative to NaBH3CN. 
 
2.2.4 2-AB Labeling Conditions 
1. Add 5µl of the 2-AB labeling Solution to each dried glycan sample. Cap and mix 
thoroughly. Tap or spin down to collect the dissolved sample in the bottom of each vial. 
2. Incubate glycan samples for 3 hours at 65°C in a heating block, dry oven, or sand tray. 
Note: Incubation periods of 2–4 hours will not significantly affect results. 
3. If insoluble particulates are present, vortex the pre-heated samples from step 5 for 30 
minutes. 
4. Following incubation, briefly spin the vials to recollect each sample at the bottom of 
the reaction vial.  
5. Allow the samples to cool to ambient temperature prior to proceeding with post-
labeling analysis. 
6. Purify the labeled glycans using Extract-Clean SPE Carbograph columns (Grace).  
7. Elute the glycans was eluted with 80% acetonitrile (0.1% formic acid). 
8.  Dry the purified glycans in a Speedvac. 
9. Reconstitute the labeled glycans in 25uL H2O and mix with acetonitrile for a final 









2.2.5 Chromatographic Conditions for High-Resolution of N-Glycans 
HPLC System: Agilent 1260 quaternary solvent delivery  
Detectors: FLD (Excitation 330nm and Emission 420nm) and PDA (Abs. 215nm) 
Column Thermostat: 45°C 
Column: Waters Xbridge Amide column, 3.5 μm, 2.1 x 150 mm 
 Mobil Phase A: 100mM Ammonium Formate pH 4.50 
Mobil Phase B: 80% 1-Propanol, 10% AcN, 10% H2O, 0.05% TFA 
Flow Rate: 0.5 mL/min 
Injection Volume: 25µL 
Gradient Conditions: 

























In (Chung, 2017), two different anti-grass pollen IgGs (gpIgG1) were developed 
to enhance certain glycosylation features, in addition to maintaining the wild-type.  
Specifically, gpIgG1 (wild-type), gpIgG1F241A from CHOK1 cells (incorporating a 
mutation of F->A to enhance glycosyltransferases accessibility to N297), and gpIgG1 
from a CHO 2,3-sialyltransferase knock-out cell line.  In (Chung, 2017) MALDI-TOF 
glycoprofile analysis of these IgGs from different CHO cell lines were performed to 
observe the glycosylation profile of each type, shown in Figure 10.   
 
 
Figure 10: MALDI-TOF glycoprofile analysis of IgGs from different CHO lines. (a) 
Glycoprofile analysis of gpIgG1 and single amino acid mutants expressed from CHOK1 
and CHO23KO cells. N-glycan analysis of gpIgG1 from CHOK1 cells from a previous 
study (Chung et al. 2016) (Panel A), gpIgG1F241A from CHOK1 cells (Panel B), and 
gpIgG1 from CHO23KO cells (Panel C).  This figure was adapted from (Chung, 2017). 
 
Each mAb type was then subjected to n-glycan analysis via HILIC-FD, as 
described in the methods section.  However, the wild-type sample (shown in Figure 10a) 
was apparently too old ~4 years, and resulted in no glycan peaks observed.  Data not 
shown.  The results of the analyses are shown in Figures 11-14.   The relative abundance 
of each glycoform was calculated by measuring peak area of a certain glycoform and 
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dividing by the total of all identified glycan peaks using the ChemStation software.  
However, as results were not able to identity due to lack of standards, no conclusions 
could be drawn as to the ratios of which peaks corresponded to what area, therefore this 
data was omitted. 
 
Figure 11: HILIC-FD N-glycan analysis of gpIgG1F241A from CHOK1 cells. 
 
 
Figure 12: Zoom-in of HILIC-FD N-glycan analysis of gpIgG1F241A from CHOK1 
cells. 
 
Figure 13: HILIC-FD N-glycan analysis of gpIgG1 from CHO23KO cells. 
 
 





2.3.1 HILIC-FD glycan analysis of gpIgG1F241A from CHOK1 cells. 
2.3.2 HILIC-FD glycan analysis of gpIgG1 from CHO23KO cells. 
 
Through comparison of Figures 10-14, some interesting observations can be 
made.  It is unfortunate that the wild-type IgG glycoprofile shown in Figure 10a, did not 
generate usable data as the other samples clearly show similar glycoprofiles across both 
methods.  The sample shown in Figure 10B does match the profile of Figures 11-12.  
Similarly is the case for the sample shown in Figure 10C matching the profile of Figures 
13-14.  MALDI-ToF is a semi-quantitative metho,d thus rendering only relative 
quantification on the basis of sample comparison.  It was the goal of this method to 
establish a quantitative n-glycan analysis method, however, without standards to identify 
each glycoform, an then to construct standard curves for each sample, this work must be 
carried out a later time. 
 
2.4 Discussion 
The glycosylation status of proteins is an inherent source of heterogeneity, where 
cell line selection, process parameters and production scale all contribute to affecting the 
glycoform distribution (i.e. the story Genzyme’s Myozyme).   Therefore, analysis of the 
glycan pattern is an important issue for characterization studies and quality control in 
research and biopharmaceutical industries.  Pharmaceutical regulatory agencies 
worldwide have established the general principles for process- and quality-control and 
risk management in biopharmaceutical manufacturing.  The glycan method developed is 
to address and determine the appropriate limits, ranges (e.g. tolerances) and distributions 
(e.g. required features) of the N-linked glycosylation profiles of biotherapeutic 
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glycoproteins to ensure the desired product quality, safety and efficacy.  Through careful 
inspection of glycosylation profiles during product development, scale up, process 
changes and production may allow the identification of factors or methods that affect 
glycan patterns or heterogeneity. These observations may in turn isolate potential 
glycosylation control points to selectively enable production of preferred glycoforms for 
specific functional purposes. 
In this study, glycans were derivatized with the 2-AB fluorescent label producing 
a neutrally charged, highly stable amide bond between the label and glycan.  The labels 
charge neutrality helps to enhance separation of neutral and negatively charged glycans, 
and furthermore allows stoichiometric detection, as each N-linked glycan is derivatized 
on the reducing terminus with one fluorescent tag, thereby reducing the complexity of 
data interpretation.  A drawback of this technique is that it requires additional steps to 
attach the label and clean-up the glycans prior to chromatography, unlike MS or PAD.  
Following labeling, HILIC-FD was employed for separation of the glycoforms.  HILIC 
separations are based on a variation of normal-phase chromatography in which the 
mobile phases consist of polar aqueous and miscible aprotic organic character with the 
stationary phase being of polar hydrophilic amine/amide-derivatized silica, polymeric or 
“hybrid-type”.  The mechanism of HILIC is such that the eluents pH and ionic strength 
affect the separation as an increasingly aqueous gradient then separates the analytes on 
the basis of their relative polarity and solvation.  However, the selectivity of this method 
is hindered by compounds of similar polarity.  In the study of glycoanalysis presented 
here, HILIC separations of glycans was achieved through progressive gradient of 80% 1-
Propanol, 10% AcN, 10% H2O, 0.05% TFA into 100mM ammonium formate  pH 4.5 on 
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a amide-derivatized silica column.  Through comparison of the N-glycan chromatrograms 
to the MALDI-ToF data, the results from the two orthogonal analysis methods 
demonstrate a strong measure of consistency in the types and amounts of N-linked 
glycans in the mAbs tested.  Thus validating the accuracy and sensitivity of the method 
presented herein.  Future studies would need to incorporate a standard panel of typically 
observed N-glycans, alternatively use of a Glucose Unit (GU) ladder would aid in the 
identification of glyco-forms through comparison of their retention times with the ladder, 
and correlating this with known glyco-databases.  Additionally, through construction of 
calibration curves, absolute quantification of each glycoform could be performed 




























Chapter 3: Amino Acid Analysis 
3.1 Introduction 
 
Naturally occurring L-amino acids are required for protein synthesis and are 
precursors for essential molecules, such as co-enzymes and nucleic acids (Bushan, 
2001).  These molecules exhibit a wide spectrum in their chemical and physical 
properties such as polarity, hydrophobicity and solubility (Rahman, 2014), see Figure 15 
below for their chemical structures and pKa’s.  
 
 
Figure 15: The chemical structures and pKa’s of amino acids. 
 
This molecular diversity is the main challenge in achieving quantitative analytical 
chemistry in a single method with minimal technical variations (Rahman, 2014). 
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Metabolic profiling on cells (the metabolic fingerprint) and on the cell growth medium 
(the metabolic footprint) are the complimentary approaches to study pathway(s) and 
inter-conversion(s) of compounds such as amino acids or carbohydrates (Rahman, 2014).  
Amino acid analysis (AAA) is a fundamental biochemical technique used in peptide, 
protein and bio-active metabolites across research, clinical facilities and industrial 
processes.  AAA allows for the determination of the amino acid composition or content 
of proteins, peptides, tissues, biological fluids, and other samples containing amino 
groups within their molecular structure.  AAA allows for amino acid quantitation of 
free amino acids such as those found in cell media, as well as amino acids released 
from macromolecules or cell hydrolysates.  As this analytical tool may be used to 
monitor or detect the topology and operation of cellular metabolism (Millard, 2017), it 
is highly useful in a metabolic engineering laboratory for the determination of amino 
acid fluxes, biomass composition, and mass isotopomer distributions (MID) (Millard, 
2017).  Metabolic Flux Analysis (MFA) experiments require accurate and precise 
isotopomer measurements (Antoniewicz, 2017), as the mass isotopomer distributions 
provide additional equations through atom mapping matrices in stoichiometric material 
balances. Metabolic flux analysis (MFA) provides a powerful approach to map 
intracellular carbon flows of cultured cells and thereby elucidate the functional behavior 
of entire biochemical networks, as opposed to studying individual reactions or nodes in 
isolation (Sauer, 2006).  However, it’s progress is stifled due to lack of better analytical 
chemistry methodologies discussed below. 
Among the various chromatographic methods for the analytical separation and 
quantification of amino acids; ion chromatography, gas chromatography, and liquid 
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chromatographic techniques are the most frequently used (Peace, 2005).  AAA methods 
based on precolumn derivatization procedures have become a popular alternative to the 
traditional postcolumn derivatization techniques based on ion-exchange separation of 
the underivatized amino acids (Cohen, 2003). The major reasons for this include greater 
sensitivity, faster analyses, and the ability to use less expensive, more flexible HPLC 
instrumentation rather than dedicated amino acid analyzers (Cohen, 2003).  Gas 
Chromatography (GC) can also be used, and in certain cases instrumentation 
availability or operation costs can make it a better choice. However, the polar nature of 
amino acids requires derivatization prior to GC analysis.  For GC analyses, a silylation 
reagent N-tert-butyldimethylsilyl- N-methyltrifluoroacetamide (MTBSTFA) is used for 
the derivatization of amino acids. MTBSTFA, forms tert-butyl dimethylsilyl (TBDMS) 
derivatives when reacted with polar functional groups containing an active hydrogen, 
resulting in the substitution of the active hydrogen atoms of OH, NH, and SH groups by 
a TBDMS moiety. The consequent reduction of the dipole–dipole interaction of the 
target molecules results in their transformation into molecules of low polarity, 
increased volatility, and high thermal stability, rendering them amenable to study by 
GC-MS.  Under certain reaction conditions, the majority of the amino acids produce 
one derivative, however, some amino acids under certain reaction conditions can 
produce multiple derivatives.  Specifically, the amino acids asparagine, glutamine, and 
tryptophan can produce multiple adducts, rendering their quantitation difficult 
(Stenerson, 2011).  In the case of these amino acids, a modification in the reaction 
conditions, such as, lowering the temperature or changing the reaction time, may 
prevent this from occurring (Stenerson, 2011). Asparagine, glutamine and tryptophan 
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produce multiple reaction products as a result of the TBDMS derivatization, which 
prevents accurate determination of MID’s.  As the majority of MFA labs employ GC-
MS, they are only able to measure 16 of the 20 natural amino acids.  This why current 
Metabolic Flux Laboratories, despite immense mathematical progress, do not possess 
the analytical chemistry capability for determining all 20 amino acids. 
To overcome the limitations in GC based analyses and because HPLC 
instrumentation is more versatile to various work flows, this work focuses on HPLC-
based AAA.  Among the more widely employed derivatization reagents are 
orthophthalaldehyde (OPA) and Edman’s reagent, phenylisothiocyanate (PITC), for 
which there are numerous publications illustrating their utility. OPA, however, has the 
significant drawback in that it does not react with secondary amino acids, and some of the 
derivatives, notably those with Gly and Lys, are unstable (Cohen, 2003).  PITC, while 
reactive with the secondary amino acids, also produces somewhat unstable derivatives, 
notably with Asp and Glu, which slowly cyclize from the desired phenylthiocarbamyl 
moieties to their respective phenylthiohydantion derivatives (Cohen, 2003). In addition, 
excess PITC must be removed, typically by evaporation, prior to HPLC analysis to avoid 
column contamination and poor chromatographic separation (White, 1986).  A 
noteworthy feature of the analysis with PITC is the quantification of secondary amino-
acids, such as proline and hydroxyproline. In contrast to post-column ninhydrin detection 
or ortho-phthalaldehyde (OPA) derivatization, the proline and hydroxyproline PTC 
derivatives have the same chromophore and approximately the same molar response as 
other amino-acids (White, 1986). There is thus no need to suffer reduced sensitivity or to 
employ a second detector for these secondary amino-acids (White, 1986).  Cohen and 
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Michaud introduced 6-aminoquinolyl-Nhydroxysuccinimidyl carbamate (AQC) for 
precolumn derivatization (Cohen, 1993).  This reagent reacts smoothly with primary and 
secondary amines to produce stable unsymmetrical urea derivatives that are highly 




Figure 16: Chemistry of the AccQ·Tag Reaction. Derivatization of  AQC with primary 
(1”) and secondary (2”) amines with AQC, and hydrolysis reaction of excess reagent. 
 
The reaction products are generated within seconds, and in a somewhat slower 
reaction, excess reagent is hydrolyzed to yield 6-aminoquinoline (AMQ), carbon dioxide, 
and N-hydroxysuccinimide (NHS) (Cohen, 2003). Key to the design and implementation 
of this method are the fluorescence properties of the derivatized amino acids and AMQ.  
While both have excitation maxima approx 248 nm, they have radically different 
emission maxima, with the AMQ near 520 nm, and the amino acid products at 395 nm 
(Cohen, 2003). This shift in emission maximum allows the derivatization mixture to be 
injected onto the HPLC column without need for excess reagent removal.  Studies on 
derivatization conditions demonstrate excellent derivative yield over the pH range 8.2-
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10.0 (Cohen, 2003). Maximal yields are observed with a molar reagent excess of 
approximately three or greater. The reaction is extremely tolerant of common buffer salts 
and detergents, with no discernible decrease in reaction yield with well-buffered samples 
(Cohen, 2003).  Fluorescence detection permits highly sensitive analyses with detection 
limits ranging from 50–300 fmol (Cohen, 2003). Combination of HPLC with mass 
spectrometry makes analyses very reliable in instances of co-eluting compounds, where 
optical detection fails to discriminate between these co-eluting species (Bhushan, 2001). 
Use of stable isotopes as internal standards also enhances sensitivity of the method 
(Bhushan, 2001).  Although there are many techniques available for AAA, and the 
sample can be analyzed quickly, accurately, and sensitively, several precautions need to 
be taken in order to obtain reliable data on the concentration of amino acids.  These 
include the sample collection, centrifugation, storage conditions, and most importantly 
the deproteinization method.  The presence of remaining proteins can introduce artifacts 
into the analysis that interfere with the resolution and quantitation of species present in 
the sample (Bhushan, 2001).   
Calculation of amino acid flux is described below by the method of (Glacken, 
1988).  In general, the flux of any compound can be calculated by first experimentall 
determining: the growth rate,  (hr-1), the change in cell count or dry weight over a 
specified time interval, dX (cells*106/hr), and the change in the compound over that same 
specified time interval, dCi (moles/hr).  Then dividing the change in compound 
concentration in time by the change in cell count/dry weight in time and multiplying by 
the specific growth rate, gives the flux of compound Ji, giving units of mol/cell-hr or 
mole/gDW-hr, see equation below. 
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The flux is the rate of change in substrate or product concentration (-d[S] and d[P], 
respectively) per unit time (dt) per cell number or mass basis.  The specific rates of 
production of amino acids, Nova metabolites, product titer and biomass are then 
combined with carbon material balances via a reaction network (coupled, linear 
differential equations) to estimate the metabolic fluxes at steady state using an 


















3.2 Materials and Methods 
Waters AccQ•FluorTM Reagent Kit (WATERS, Pn: WAT052880) 
*The Waters AccQ•Fluor Reagent Kit contains sufficient reagent for up to 250 analyses. 
Heat Block 
Vortexer 
Acetonitrile (Fisher Scientific, LC grade) 
Ammonium Hydroxide (Fisher Scientific) 
Formic Acid (Fisher Scientific) 
Hydrochloric Acid (Sigma Aldrich) 
pH Meter 
Milli-Q H2O on house tap 
Wattman 0.22µm Filter, and suction unit 
2x Agilent Eclipse EC-C18 2.7m 150x2.1mm HC columns 
Agilent 1260 HPLC with quaternary solvent delivery with FLD, PDA, and Column Oven 
 
3.2.1 Preparation of Samples, Cell Media and Biological Fluids  
1. Remove Media from culture flask using a serological pipette.  
2. If suspension culture, centrifuge at 3000g for 5 minutes at 4C to pellet cells, and 
collect supernatant. 
3. Combine fluid with 100% Acetonitrile in 1:1 mixture to pellet the proteins. 
4. Centrifuge the fluid at 16000g for 30 minutes at 4C. 
5. Carefully collect the supernatant without disturbing the protein pellet. 
6. Filter the supernatant through a 0.22m filter. 
 
3.2.2 Preparation of the AccQ•Fluor Derivatization Reagent 
1. Preheat a heating block to 55 °C. 
2. Tap Vial 2A lightly before opening to ensure all AccQ•Fluor Reagent Powder is at the 
bottom of the vial. 
3. Rinse a clean micropipette by drawing and discarding 1 ml of AccQ•Fluor Reagent 
Diluent from Vial 2B.  
4. Transfer 1.0 ml of AccQ•Fluor Reagent Diluent From Vial 2B to the AccQ•Fluor 
Reagent Powder In Vial 2A. 
5. Cap Vial 2A lightly and vortex for 10 seconds. 
6. Heat Vial 2A on top of heating block, vortex occasionally, until the powder dissolves. 
Do not heat longer than 10 minutes. Reconstituted AccQ•Fluor Reagent is approximately 
10 mM 
AQC in acetontrile. 
Note: You can store the reconstituted AccQ•Tag reagent in a desiccator 
at room temperature for up to one week. The AccQ•Tag reagent reacts 
with atmospheric moisture so seal the container tightly when not in 
use and DO NOT refrigerate. 
7. Amino acid calibration stock solution (2.5 mM in 0.1M HCl) (Pierce Chemical Co. or 
Sigma Chemical Co.).  
8. Working calibration mixture: Mix 40 μL of amino acid stock solution (2.5 mM) with 
960 μL of water to give a solution with 100 pmol/μL of each AA.  
9. 20 mM HCl: Mix 10 μL of constant boiling HCl with 3 mL of HPLC-grade water. 
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Note: 20 mM HCl is used to reconstitute protein hydrolysates or dried amino acid 
powders. 
 
3.2.3 Derivatization of Samples and Standards 
1. Preheat a heating block to 55 °C. 
2. Add 60 μl of AccQ•Fluor Borate Buffer to the reconstituted 
sample in the 6 x 50 mm sample tube and vortex. 
3. Add 20 μl of AccQ•Fluor reagent. Vortex immediately for 
several seconds. 
4. Allow to incubate for one minute at room temperature. 
5. Transfer the contents of the tube to an autosampler vial low 
volume insert (LVI). Cap with a silicone-lined septum. 
6. Heat the vial In a heating block for 10 minutes at 55 °C.  




































3.2.4 Amino Acid Analysis Chromatographic Conditions 
HPLC System: Agilent 1260 quaternary solvent delivery  
Detectors: FLD (Excitation 250nm and Emission 395nm) and PDA (Abs. 254nm) 
Column: 2x Agilent Eclipse EC-C18 2.7m 150x2.1mm, connected in series 
Flow Rate: 0.475 mL/min 
Column Oven: 37ºC 
Injection Volume: 5µL 
Mobil Phase A: 100mM Ammonium Formate pH 4.40 
Mobil Phase B: Acetonitrile (Fisher HPLC grade) 
Mobil Phase C: H2O (Mili-Q house tap) 
Mobil Phase D: 60% Acetronile / 40% H2O (HPLC grade) 
Gradient Conditions: 













Time (min) %A %B %C %D
0 100 0 0 0
0.5 96.5 3.5 0 0
11 95.4 4.6 0 0
13 89 11 0 0
25 86 14 0 0
25.1 93.3 0 0 6.7
28.2 91.9 0 0 8.1
38 70 0 0 30
58 20 0 0 80
60 0 0 0 100
62.5 0 95 5 0
74.5 0 95 5 0
85 0 0 0 0
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3.3 Results  
 
3.3.1 Amino acid profile of F-12K Nutrient medium Formulation. 
 
F-12K Nutrient media was spiked with 13.5mg/L of Norvaline for use as an 
internal standard. Following derivatization with the AQC, the resulting HPLC 
chromatogram for F-12K is shown in Figure 17. The concentrations of the F-12K amino 
acid components are listed in Table 4, these values were taken from Corning cellgro. 
 
 



























3.3.2 Amino acid profile of RPMI 1640 Formulation. 
 
RPMI 1640 formulation media was spiked with 13.5mg/L of Norvaline for use as 
an internal standard.  No standard was available for hydroxyproline however comparison 
of Water’s elution order for the AccQ derivatized amino acids established that Hyp elutes 
prior to Pro. Following derivatization with the AQC, the resulting HPLC chromatogram 
for RPMI 1640 is shown in Figure 18.  The concentrations of the RPMI 1640 amino acid 
components are listed in Table 5, these values were taken from Corning cellgro. 
 
 
























The results demonstrate that the method is able to not discern differences in the 
concentrations of medias but also their composition.  Future work would establish 
calibration curves for each individual amino acid component and then use this calibration 
to determine changes in the media composition of cell culture over time.  This data would 




A drawback of some pre- and post-column derivatization assays is the 
requirement of an automated pretreatment multi-functions autosampler. This is an 
autosampler that is able to perform injector programming that mixes desired functions of 
solutions, and enables consistent sample preparation. Use of o-phtalaldehyde (OPA) and 
9-fluorenyl methyl chloro formate (FMOC) to derivatize primary and secondary amino 
acids, respectively, requires a constant reaction time be maintained with the automated 
autosampler derivatization.  Manual operation of the derivatization reaction results in 
repeatability issues over intra- and inter-day RSD’s.  Thus the advantage of using the 
Water’s AccQ reagent is clear, as the reactants can simply be mixed without concern of 
reaction time due their short half-life. Furthermore, unlike OPA/ FMOC, ninhydrin and 
other labels, AccQ derivatives have the same chromophore and approximately the same 
molar response as other amino-acids.  AAA using AccQ resulted in the separation of 
complex amino acid mixtures, such as free amino acids present in cell culture fluids.  
Precise control of eluent pH and organic solvent gradient slopes were determined to be 
essential for optimum resolution, particularly in the preparation mobile phases.  The 
sensitivity, calibration, inter- and intra-day precision, reproducibility and molecular 
stability of each targeted metabolite still remains to be assessed under the experimental 
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conditions.  Furthemore, the choice of volatile mobil phases makes this method readily 
amenable to ESI-MS for molecular weight verification and obtaining the MIDs in isotope 
labelling experiments. This AAA method also has advantages to studying cellular 
metabolic responses to media composition changes and the corresponding impact on 
glycosylation during the culture (Gillmeister, 2009).  Several amino acids have been 
known for the effects on N-linked glycosylation and used for glycan modulation.  Raising 
glutamine concentrations or adding ammonia directly to the culture led to decreased 
galactosylation (Gillmeister, 2009).  Increased consumption of glutamine is shown by 
many cell lines, but much of the nitrogen provided by this substrate is lost to the 
production of ammonia and alanine (Sha, 2016).   Resultantly the ammonia byproduct 
can be detrimental to sialylation and galactosylation (Gillmeister, 2009; Sha, 2016).  
Supplementation with threonine, proline, or glycine was found to result in an increase in 
the glycan galactose and sialic acid content (Sha, 2016).  A correlation was reported 
between the distribution of galactosylated glycoforms and the concentration of Asn in the 
media (Sha, 2016).  Changing nutrient availability and cell densities give rise to 
transitions between distinct growth phases (i.e., exponential, stationary, and decline).  
During early growth phases concentrations of lactate, ammonia, and other waste products 
accumulate to concentrations that inhibit cell growth and antibody production and impact 
protein glycosylation during later phases.  While minimizing wasteful byproduct 
accumulation has always been a goal of the biopharmaceutical industry, it still remains an 
unresolved and challenging issue. Furthermore, many production cultures will shift from 
net production to net consumption of these byproducts during the bioprocess run (Nolan 
and Lee, 2011); however, the regulatory mechanisms that control these changes remain 
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elusive.  Hence the need to accurately monitor amino acid expression levels as a function 
of cellular condition, stress, or other perturbation of the cell and how those changes 
correlate to altered glycan composition.  While substantial improvements in bioprocess 
rates and titers have been made, the ability to precisely quantify cell metabolism 
throughout the production run is essential to further understand and optimize the 



































Chapter 4: Nucleotides and Nucleotide Sugars Analysis 
4.1 Introduction 
 
Nucleotide Sugars are ubiquitous metabolites that are the activated substrates for 
the biosynthesis of carbohydrate molecules.  Furthermore, the interconversion of one 
monosaccharide to another, e.g. glucose to galactose, occurs in their activated forms 
(Ramm, 2004).  As obligate precursors of glycosylation, the presence of nucleotide sugar 
pools provides strong evidence for cellular glycosylation reactions (López-Gutiérrez, 
2017).  To date, 30 different nucleotide sugars have been identified in plants, at least 70 
are known in bacteria, 12 in humans, and up to 16 in fungi (Bar-Peled, 2011).  Previous 
studies have found that the availability of nucleotide sugar donors determines the 
macroheterogeneity and also the microheterogeneity of the carbohydrates bound to the 
protein (del Val, 2015).  Investigations into the metabolism of nucleotide sugars requires 
a generally applicable, rapid and robust analytical assay which should enable the 
separation, unambiguous structural characterization and quantitation of substrates, 
intermediates and end products (Ramm, 2004).  Several attempts have been made to 
extract and quantify these compounds from cells in culture using analytical techniques 
such as high-performance anion-exchange chromatography, reverse-phase ion-pairing 
high-performance liquid chromatography, and capillary electrophoresis (del Val, 2015).  
Despite encouraging results, many of the available analytical techniques have limitations 
such as the length of analysis time (>50 min), detection of certain species, based on 
sophisticated detection or separation methods, or laborious preparation of the mobile 
phase(s) (del Val, 2015).  Prior to performing the analytical method, recent reports 
suggest that cell culture sample treatment prior to extraction (washing and quenching), as 
well as the metabolite extraction protocol, may greatly influence the measurement of 
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intracellular metabolite pools (Del Val, 2015).  This is due to the fact that some 
intracellular metabolites are turned over on a short time scale, where rapid cold-
quenching is necessary to capture an accurate snapshot of intracellular metabolism 
(Templeton, 2009; Sellick, 2009).  Ideally, tedious sample preparation should be avoided 
which could result in loss of analytes and decomposition of labile compounds.  The 
objective of these procedures are to ensure that (i) the extraction method allows for 
reproducible retrieval of the desired metabolites, (ii) the metabolite pools to be extracted 
are representative of the metabolic state of the cells at the moment of extraction, and (iii) 
components from the cell culture medium do not contaminate the intracellular samples 
(del Val, 2015).  This chapter describes an optimized method for nucleotide and 
nucleotide sugar extraction and identification from CHO cells, which in principle is 























4.2 Methods & Materials 
 
PBS (cat # 70011-044; ThermoFisher, Grand Island, NY, USA) 
Milli-Q Water, house tap 
75.0% ice cold ethanol (cat # 459836; Sigma, St. Louis, MO, USA) 
ENVI-Carb SPE column (cat # 57109-U; Sigma, St. Louis, MO, USA) 
Acetonitrile (cat # 34998; Sigma, St. Louis, MO, USA) 
Methanol (Sigma-Aldrich) 
Trifluoroacetic acid (cat # 302031; Sigma, St. Louis, MO, USA) 
Potassium Phosphate (Sigma-Aldrich) 
tetrabutylammonium hydrogensulphate (Fisher) 
Ammonium Bicarbonate (cat # A6141; Sigma, St. Louis, MO, USA) 
Triethylamine (Fisher) 
Acetic Acid (Sigma-Aldrich) 
Quenching Solution: 0.85% (w/v) of the aqueous portion which is a 60/40 mixture of 
methanol/AMBIC pre-cooled to −40°C 
The purified monosaccharides, nucleosides and nucleotide sugars: N-
Acetylgalactosamine (GalNAc), Mannose (Man), Sialic Acid (NeuAc), N-
Acetylglucosamine (GlcNAc), Glucuronic Acid (GlcUA), Galactose (Gal), Glucose 
(Glc), Adenosine Monophosphate (AMP), Adenosine Diphosphate (ADP), Adenosine 
Triphosphate (ATP), Uridine Monophosphate (UMP), Uridine Monophosphate 
(UDP), Uridine Monophosphate (UTP), Guanosine Monophosphate (GMP), 
Guanosine Diphosphate (GDP), Guanosine Monophosphate (GTP), Cytosine 
Monophosphate (CMP),  Cytosine Diphosphate (CDP),  Cytosine Triphosphate 
(CTP), UDP-Gal, UDP-Glc, UDP-GalNAc, UDP-GlcNAc, CMP-Neu5Ac, GDP-
Man, GDP-Fuc, and GDP-Glc  were all purchased from Sigma Aldrich, St. Louis, 
MO, USA. 
Buffer A for HPLC analysis: 100 mM potassium phosphate buffer (K2PO4) (pH 
6.40) supplemented with 8 mM tetrabutylammonium hydrogensulphate (TBAHS) 
Buffer B for HPLC analysis: 70% buffer A plus 20% acetonitrile 
Handy Sonic Disruptor (Tomy Seiko Co. Ltd., Tokyo, Japan) 
Speed Vac Concentrator (Labconco Co., Kansas City, MO) 
Lyophillizer 
Shimadzu LC-10ai binary HPLC system equipped with a UV & FLD detector 
(Shimadzu Corp., Kyoto, Japan) 
Inertsil ODS-2 (particle size: 3 μm; 150 × 4.6 mm; GL Science, Tokyo, Japan) 
 
4.2.1 Metabolite Cold-Quenching and Extraction of Aqueous Phase Metabolites 
1. At each sample time point, transfer an aliquot of culture medium containing 
approximately 9 million CHO cells (cell counting performed by hemotocytometry, see 
supplemental information for details) into a 15mL falcon tube. 
2. Rapidly place into the quenching solution at a ratio of 1:5 cells to quench solution.  
3. Following the cold-quench, metabolite extraction is performed using the Folch method 
(Folch, 1957) with use of a sonicator to help disrupt the cell membrane.   
4. Remove the aqueous portion of the metabolite extraction, as this phase contains the 
nucleotides and nucleotide sugars. 
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5. Lyophillize the aqueous extract. 
4.2.2 Purification of sugar nucleotides by Solid-Phase Extraction (SPE) 
Chromatography 
1. Place a 1 mL/100 mg ENVI-Carb SPE column in a 15 mL conical tube. 
2. Equilibrate the column by adding 1 mL of 80% acetonitrile in 0.1% trifluoroacetic acid 
and spin at 60 × g for 45 s (room temperature). Repeat twice. 
3. Add 1 mL of ultrapure water to the column and spin as described in step 1. Repeat 
once. 
4. Reconstitute the dried cell samples (generated from extraction from step 5) in 2 mL of 
10 mM ammonium bicarbonate. 
5. Add 1 mL of the dissolved sample to the column and spin as in step 1. Repeat with the 
other half of the sample. 
6. Collect flow-through and enrich by re-applying the sample to the ENVI-Carb column 
in 1 mL fractions (same as step 5). 
7. Wash the column with 2 mL of ultrapure water, 2 mL of 25% acetonitrile, 1 mL of 
ultrapure water, and 2 mL of 10 mM TEAA buffer (pH 7) and spin after each wash as 
described in step 2. 
8. Collect SPE Envi-Carb column(s) and place into a new 15 mL conical tube. 
9. Elute the bound sugar nucleotides with 2 mL of 25% acetonitrile in 50 mM TEAA 
buffer (pH 7). Spin and pool as described in step 2. 
10. Transfer the purified sugar nucleotides to a 2 mL eppendorf tube. 
11. Lyophillize the samples to remove the TEAA. 
12. Reconstitute the samples in 100uL H2O. 
 
4.3.3 Fluorescent Assisted Carbohydrate Electrophoresis (FACE) 






















4.3.4 Ion Pair Reverse Phase Chromatography (IP-RPC) Conditions for High-
Resolution of Nucleotide Sugars 
HPLC System: Shimadzu LC-10ai binary HPLC system equipped with a UV & FLD 
detector (Shimadzu Corp., Kyoto, Japan) 
Detector: PDA (Abs. 254nm) 
Column Thermostat: Ambient 
Flow Rate: 1 mL/min 
Injection Volume: 20µL 
Column: Inertsil ODS-2 (particle size: 3 μm; 150 × 4.6 mm; GL Science, Tokyo, Japan) 
Mobil Phase A: 100 mM potassium phosphate buffer (K2PO4) (pH 6.40) supplemented 
with 8 mM tetrabutylammonium hydrogensulphate (TBAHS) 
Mobil Phase B: 70% buffer A plus 30% Acetonitrile 
Gradient Conditions: 



























4.3.1 FACE technique results  
 
Pancreatic cancer cells were used to establish the FACE techniques ability to 
handle cellular extracts.  Briefly, 10^6 cells were isolated, washed, then spiked with 10g 
2-Deoxy-Glucose (2DG) immediately prior to cell extraction (2DG is an unnatural 
monosaccharide that was used to determine the efficiency of the subsequent nucleotide 
sugar purification steps from free monosaccharides, e.g. any 2DG left over in the final 
sample would indicate that clean-up steps could not remove free monosaccahrides and 
hence give false signal on the FACE gel), then samples were dried, and reconstituted and 
spiked with 100 nmol of UDP-Arabinose (UDP-Ara) (to test for nucleotide sugar 
extraction efficiency of purification), then acid hydrolyzed to release sugars from 
nucleotide sugars, then labelled with 2-aminoacridone, and lastly ran on a 30% 





Figure 19: FACE gel of monosaccharide standards. 
 
One of the most remarkable things about the FACE technique is the high 
resolution observed between UDP-GlcNAC and UDP-GalNAc as seen in Figure 19.  
Indeed no other method comes anywhere near this resolution.  However, Glc and Gal 
appear very near each other.  The sharpness of the bands could also use improvement, 





Figure 20: FACE gel of standards 2DG and Arabinose alongside spiked PANC cell 
extracts.  Upper circle shows the presence of some 2DG in extracts indicating washes not 
able to 100% purify out free monosaccharides . As a result, the lower circle (Glc-NAc 
band) is a superposition of both free Glc-NAC and UDP-GlcNAc. The UDP-Arabinose 
internal standard was not spiked into the control cells which is why the band is absent. 
 
Figure 20 shows the comparison of standards used as internal controls in the assay 
alongside cell extracts, with the control sample not being spiked with UDP-Ara.  The 
slight presence of 2DG in the samples means that the carbo-column was not able to 100% 
purify out free monosaccharides.  Therefore, there is probably some contamination of the 
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all bands present with some small amount of free monosaccharides.  However, 
quantification of free monosaccharide versus activated sugar was not accomplished in 
these studies.   The UDP-Arabinose spike in shows that nucleotide sugars are indeed 
recoverable in a complex matrix such as a cell extract.  The blurring of the bands renders 
them difficult to quantitatively measure, instead this technique offers a more qualitative 
look at the cellular status of nucleotide sugars at the time of extraction.  This limitation in 
quantitation provided the impetus for development of an HPLC based method. 
 
4.3.2 IP-RPC Results of Nucleotides and Nucleotide Sugars 
All nucleotides, nucleoside sand nucleotide sugars standards were previously 
reconstituted by Yuzhou Fan in 2013, and kept frozen at -80C prior to use.  
Unfortunately, even though vials listed 100nmol/µL, the samples did not appear to have 
consistent dilutions (data not shown), presumably, the molar response ratios are different 
resulting in different peak areas, however no confirmation of concentrations could be 
made thus preventing quantitation.  None the less, the standards did give excellent 
qualitative results in terms of observed retention times, refer to Figure 21 for an overlay 




Figure 21: Overlay of Nucleotides and Nucleotide Sugar Standards.  The retention times 
of the compounds are listed on the right. 
 
Since the method was shown to have resolution, reproducibility, and analyte 
retention, CHO cell extracts were then examined.  To be able to see a large difference 
between cells, one CHO cell line was treated with the high-flux analog 1,3,4-O-Bu3-
ManNAc at a concentration of 100µM, and a control sample was fed glucose as standard 
carbon source at a concentration of 15mM, refer to “Treatment of Cultures With 1,3,4- 
O-Bu3ManNAc and ManNAc” in supplemental material.  The results of the CHO cell 






Figure 22: Comparison of purified Nucleotides and Nucleotide Sugars from CHO cell 
extracts.  CHO cells were ManNAc-analog-fed (blue) vs non-fed (gold). ~9.5x10^6 CHO 
cells were subjected to extraction and purification of Nucleotide Sugars.  
 
To determine the peak identities of the CHO cell extracts, the nucleotides and 
nucleotide sugars standards were overlaid with the analog fed nucleotide sugar extract, 
shown in Figure 23.  However, as can be seen there appeared co-elution of the UDP-
GalNAc and UDP-GlcNAc peak, which even though the standards separated, additional 
molecules could be co-eluting there as well.  Without additional standards to establish 





Figure 23: Overlay of Nucleotides and Nucleotide Sugars Standards and of ManNAc-
analog-fed CHO cell extract (purple). 
 
To observe if the high-flux analog feeding strategy had any effect on the levels 
CMP-Neu5Ac in CHO cells, a CMP-Neu5Ac was run to determine its’ retention time.  
CMP-Neu5Ac eluted at ~3.75 min., as shown Figure 24.  Figure 24 also shows the 




Figure 24: Overlay of CMP-Neu5Ac standard (pink) and of purified Nucleotides and 
Nucleotide Sugars from CHO cell extracts that were ManNAc-analog-fed (blue) vs non-
fed (gold). 
 
Having established some of the peak identities, some observations can be noted 
from Figures 21-24.  Figure 22 clearly shows substantial remodeling of nucleotide and 
nucleotide sugar cellular metabolism as shown by the difference in peak heights between 
treated vs non-treated CHO cells.  Clearly, the levels of nucleotides and nucleotide sugars 
were perturbed following the change in carbon source to the high flux analog.  
Furthermore, substantial differences appear in the levels of UDP-Gal and UDP-Glc at ~5 
min., as well as alterations in the levels of UDP-GlcNAc and UDP-GalNAc at ~6 min.  
The most exciting finding of these results is the alteration of CMP-Neu5Ac levels in 
treated vs non-treated CHO cells.  When coupled to the glycan analysis method these 




Analysis of intracellular nucleotide and nucleotide sugar contents is essential to 
glycosylation as nucleotides are involved in the metabolism and regulation of cellular 
energy and nucleotide sugars are the donor substrates of glycosyltransferases.  Multiple 
reasons hamper the analysis and quantitation of sugar nucleotides, including the difficulty 
in isolation and purification as well as the required expensive instrumentation such as a 
high performance liquid chromatograph (HPLC), mass spectrometer (MS), or capillary 
electrophoresis (CE). This was the initial motivation behind establishing the Fluorescence 
Assisted Carbohydrate Electrophoresis (FACE) technique, as the simplicity of use, 
combined with the ability to run multiple samples at one time, gave this technique a 
distinct advantage over other established methods for the isolation and analysis of 
nucleotide sugars from cell culture models.  However, several drawbacks also plague the 
FACE technique from suitability to the requirements of the project goal.  Firstly, in terms 
of quantitation, the technique relies on densitometry, which is semi-quantitative at best, 
especially in light of the band smearing that would occur on most standards and samples.  
Secondly, the hydrolysis of the nucleotide sugar to liberate the sugar for subsequent 
fluorophore deritivation loses all information on which nucleotide the monosaccharide 
moiety was initially conjugated, e.g. UDP-Glc or ADP-Glc, as the observed signal of 
Glucose would be the combination of both in this example. Despite the FACE techniques 
cost effective, simple, and robust attributes, the method was abandoned in favor of 
HPLC-based ion-pair reverse phase chromatography (IP-RPC). 
A sensitive and reproducible ion-pair reverse-phase high-performance liquid 
chromatography (IP-RP-HPLC) method has been developed, allowing for the direct and 
simultaneous determination of several essential nucleotides and nucleotide sugars in a 
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single chromatographic run. After a Folch extraction, then solid phase extraction of the 
aqueous metabolites onto Carbo-Graph column purification, 10 molecules (4 nucleosides 
and 6 nucleotide sugars) were separated, such as AMP, ADP, ATP, CTP, UDP-Glc, 
UDP-Gal, UDP-GlcNAc, UDP-GalNAc, GDP-Fuc and CMP-Neu5Ac. The HPLC 
method was then applied to quantify intracellular levels of nucleotides and nucleotide 
sugars of CHO cells cultivated in a bioreactor batch process.  Due to the hydrophilic and 
polar character of the nucleotide sugars, chromatographic separations require the aid of 
an ion-pair reagent for providing the desired chromatographic resolution.  Presumably 
caused by almost identical pKa values, charge numbers, and polarizabilities of the 
structurally-similar nucleotide sugars, as they are diastereoisomers, attempts to separate 
the compounds proved challenging.  Especially challenging are UDP-Glc and UDP-Gal, 
UDP-GlcNAc and UDP-GalNAc, for which numerous reports cannot achieve baseline 
chromatographic resolution of these molecules.  A combinatorial approach through 
various stationary phases, column dimensions, mobile phases and pH adjustment, was 
used to optimize the separation.  Stationary phases such as Porous Graphitic Carbon 
(PGC), C4, C8 and C18, were attempted, whilst keeping constant the mobile phase and 
pH.  Although the literature reports enhanced nucleotide sugars separation using PGC, 
this was not observed in experiments, due perhaps to the column being purchased in 1992 
(~25 years old, with unknown contents ran previously despite multiple 0.1% Tri-Fluoro 
Acetic Acid in Acetonitrile cleaning washes), and its 100mm length.  Furthermore, 
because carbon is conductive, linking this stationary phase to a positively charged 
Electro-Spray Ionization source Mass Spectrometer (ESI-MS) resulted in redox processes 
occurring on the stationary phase, leading to charge accumulation on the column (which 
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in future studies requires purchase of a grounding splitter prior to the ESI).  The altered 
stationary phase properties on a run-to-run basis prevented consistent chromatography.  
As the alkyl chains on C4 and C8 stationary phases have smaller surface area available 
for adsorption compared to C18, results demonstrated poor retention and separation of 
analytes, as their limited hydrophobicity prevents the detachment of the double-layer 
around these phases when analytes undergo mass transfer onto the stationary phase.  Due 
to the extreme hydrophilicity of nucleotides and nucleotide sugars they require more 
hydrophobic stationary phases.  Hence, C18 columns, being the most hydrophobic 
column available, provided the best peak shape, separation and retention.  However, 
successful chromatography required use of an ion-pair reagent to buffer the mobile phase 
at suitable pH to control analyte ionization and avoid analyte acid-base equilibrium that 
would be deleterious for peak shape.  The ion-pair reagent functions to increase the 
dielectric strength of the mobile phases and thereby shielding the analytes electrical 
surface potential which mitigates the electrostatic interactions of the sample ions with the 
stationary phase.  Additionally, the ion reagent helps to lower the surface tension of the 
eluent as chaotropic agents help to disrupt the double layer surrounding the stationary 
phase, facilitating enhanced mass transfer through increasing accessible adsorption sites 
on the column by the analyte.  Paramount to the method, was it’s ability to be mass 
spectrometry compatible, which requires use of volatile additives to the mobile phase, as 
salts would not only suppress ionization but cause contamination of the MS source, 
adduct formation, which all will have significant consequences for the robustness of the 
method.  Tri-Fluoro Acetic Acid (TFA, Tri-Ethyl Ammonium Acetate (TEAA), Formic 
Acid (FA), were tried but none proved to offer the desired peak shape and resolution, 
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however, this could be a vendor specific issue of materials used.  Instead, the method of 
(Nakajima, 2010), resulted in the best chromatographic performance with improvements 
to the gradient conditions, column choice and column oven temperature.  Unfortunately, 
this method incorporated high salt concentrations,100mM Potassium Phosphate and 8mM 
Tert-Butyl Ammonium Hydrogen Bisulfate.  A WATERS ODS2 column proved best, as 
these columns are end-capped reversed-phase columns with higher hydrophobicity 
(surface area: 450 m2/g) than a conventional column.  Under these conditions, the 
differences in the retention times of the nucleotide sugars were remarkable, facilitating 
the detection of even trace concentrations of analytes, i.e. CMP-Neu5Ac, in the presence 
of a great excess of analyte, i.e ATP. The methods superior separation of the peaks, then 
would allow fraction collection followed by desalting of the samples prior to ESI-MS 
analysis or alternatively no desalting would be required if MS detection was done using a 
MALDI-ToF.  As light absorption is a non-selective detector, the possibility that some of 
the peaks observed contained certain contaminants in various samples or were subject to 
co-elution of compounds cannot be ruled out.  Thus, it is recommended that additional 
analyses of the same samples be done by LC-ESI-MS/MS and NMR to verify the 
absolute identities of each peak.  Future work would be to validate the analytical 
parameters, reproducibility, generate calibration curves of all detected molecules, identify 
detection limits, and establish recovery for standard mixtures and cell extracts.  
This method proved able to detect cellular metabolic differences due to changes in 
feed and media composition.  Specifically, by using the high-flux analog 1,3,4-O-Bu3-
ManNAc, where ManNAc is a precursor to the sialic acid CMP-Neu5Ac, was shown to 
enhance sialic acid production in CHO cells.  This analytical method could also be used 
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to observe species-specific differences in the concentrations and identities of nucleotide 
sugars.   This last point is highly desired by metabolic engineering laboratories who seek 
to construct missing metabolic pathways in other organisms, such the sialic acid pathway 
in insects or fungi, and wish to observe the effects of their strategies.  Certainly this 
method allows for opening up the cell from a black box to an open, fertile field; this 



















Chapter 5: A Microfluidic Bio-Reactor for In-Vitro Glyco-
Engineering 
5.1 Introduction  
 
The composition and relative abundance of monosaccharides within the 
glycoform greatly influences the bioactivity, bioavailability, and biocompatilibility of the 
therapeutic protein.  Thus, methods towards controlling the glycoform are of critical 
importance to the biopharmaceutical industry and research organizations.  However, even 
when a certain glycan variant is known to have a positive impact on biological activity, it 
remains challenging to consistently produce such a glycosylation pattern. Whilst cell line 
engineering or bioprocess optimization enable the increase of glycosylation homogeneity 
or to at least partially achieve a certain glycan pattern (Yamane-Ohnuki, 2004; Jassal, 
2001, Imai-Nishiya, 2007), these activities are time-consuming and might compromise 
other key parameters, e.g. antibody yield, and due to regulatory issues, it is normally only 
applicable at the early stages of bioprocess development (i.e., production cell line 
generation and selection) (Fan, 2017).  Additionally, the production of mAbs with a 
certain glycan pattern in analytical amounts remains uneconomical using such tedious 
approaches (Thomann, 2015).  Such drawbacks provide the motivation behind the 
development of In Vitro Glyco-Engineering (IVGE).  IVGE represents an attractive and 
facile approach to providing consistent and homogeneous glycosylation.  Despite 
enormous progress in this field, many technical problems remain.  There is yet no 
practical chemical and biological means to discriminate different specific-sites for 
introducing distinct glycans with natural linkages (Wang, 2012).    
Using IVGE, certain glycoforms can be enriched in downstream processing using 
discrete enzymatic reactions with clear kinetics and predictable outcomes (Thomann, 
 76 
2015).  Using IVGE, a sample itself might still exhibit glycan heterogeneity but selective 
changes can be introduced, e.g. conversion from low levels to high levels of galactose 
(Thomann, 2015).  Furthermore, since it can be applied on therapeutic proteins during 
downstream processing, the technology is independent from the cell line and the 
bioprocess used, uncoupling glycosylation management from the entangled processes of 
cell culture and subsequent processing, granting greater control over each.  No more 
resources wasted on uncertain tweaking of the bioprocess, leading to faster development 
as well as improved control of the manufacturing process (Thomann, 2015).  Besides the 
common use of enzymes in solution, the immobilized enzymes (enzyme reactors) have 
recently gained attention for such studies (Palm, 2005).  In contrast to the free enzymes, 
an enzyme reactor is reusable and can be connected on-line to other analytical techniques, 
such as liquid chromatography (LC) and mass spectrometry (MS), as a part of an 
integrated sample investigation and as part of an automated process (Palm, 2005).  
Enzyme reactors can thus increase the throughput of analytical assays and enhance 
productivity (Palm, 2005).  The immobilized enzymes can be classified as either support 
(carrier)-bound or support (carrier)-free. Support-free immobilized enzymes whilst 
creating a high density of enzymes (for a rapid substrate-to-product conversion), lose the 
ability to retain effective enzymatic activity in combination with good hydrodynamic 
flow properties (i.e., high perfusion flow rate of substrate) is not always preserved (Palm, 
2005).  Alternatively, the enzymes immobilized at high density on highly permeable 
supports can be a convenient and efficient route to rapid digestion provided low 
concentrations of protein (Palm, 2005).   To overcome these difficulties, this work has 
developed a chemo-enzymatic method for in vitro glycosylation remodeling 
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(glycoremodeling) of natural and recombinant glycoproteins to provide structurally 
defined, homogeneous glycoforms.  This work is objective (2) of this thesis through 
implementation of a novel and transformative scalable biofabrication process applying 
In-Vitro Glyco-Engineering (IVGE) of a lab scale quantity of natural and recombinant 
glycoproteins proteins to produce structurally well-defined, homogeneous n-glycans.  
Gains from performing IVGE: time- and cost-saving generation of glycan variants to 
develop improved and optimized glycosylation profiles without compromising other 
CQAs or product yield, improved lot-to-lot consistency which reduces risk of product 
quality variation and resulting delays, the generation of glycoprofiles which may not 
otherwise be generated and streamlined analytics in comparability studies (Thomann, 
2015).  Since it can be applied on therapeutic proteins during downstream processing, the 
technology is independent from the cell line and the bioprocess used.  This chemo-
enzymatic approach utilizes the deglycosidation activity of Endo-H for cleavage of 
heterogeneous n-glycans from the glycoprotein by hydrolysis of the glycosidic bond in 
the chitobiose core leaving only the innermost GlcNAc still attached at the Asn 
glycosylation site, a schematic of the reaction can be seen in Figure 27.  
  The choice of endoglycosidase is dictated by the glycoforms present on the 
protein, such as high-mannose (Endo-H/A/M), hybrid (Endo-H/S/M) or complex N-
glycans (Endo-S/M)(Wang, 2012), but for exploratory purposes of the technology Endo-
H was chosen out of convenience.  This chemo-enzymatic approach utilizes Endo-H 
(containing activatable tyrosine “pro” fusion tags) covalently coupled to amine-
terminated groups of pre-functionalized native oxides of silicon nano-wires (SiNW), 
Figures 25 and 26, to perform the glycoremodeling reaction in a biologically compatible 
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environment.  The dimensions of the SiNWs are about 400 nm in diameter and 7 microns 
tall.  As the SiNWs are capable of developing a capacitance ~100 farads, this build of 
charge could be used to bring proteins in solution nearer to the surface for enhanced 
catalytic rates, in addition, this charge could solid phase capture proteins from solution, 
and thereby provide a unique mechanism of separation after the reaction is done.  In 
addition, if connected the device is connected to a lock-in amplifier, using impedence 
spectroscopy one could functionalize the device into a nano-sensor to detect protein 
binding events to the surface.  It is therefore critical to keep the architecture of the device 
capable of being electrically compatible. 
 
 
Figure 25: Scanning Electron Microscopy of Silicon Nano-Wires top-view.  SEM images 
provided by Erdong Song, New Mexico State University. 
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Figure 26: Scanning Electron Microscopy of Silicon Nano-Wires zoom-in with 50° tilt.  
SEM images provided by Erdong Song, New Mexico State University. 
 
Using a top-down bio-fabrication method via dry etch Bosch process from a 
silicon single crystal wafer, these devices were elaborated by our collaborators at New 
Mexico State University/Sandia National Laboratories in New Mexico. Detailed 
description of the fabrication process will be included in a publication that is in 
preparation.  This facile process then generates a “nanostructured forest” of enzymes onto 
the bioreactor surface, characterized by a large surface to volume ratio thereby offering 
enhanced reaction rates.  In contrast to traditional in vitro methods using bulk enzymes, 
which are subsequently irrecoverable, this technology is re-usable; adding economic 




Figure 27: Schematic of Reactor deglycosidating a protein. 
 
 As Figure 27 shows, a pump would flow a protein compatible fluid such as PBS 
or buffered solution, then a diverter valve could be opened to allow entrance of protein 
solution via a syringe.  As the glycoproteins enter the reaction chamber, the Endo-H 
enzyme would then deglycosidate the proteins, generating a terminal GlcNAc (where the 
GlcNAc moiety is either Fucosylated or not, Endo-H is reactive towards both species).  
Then the deglycosylated protein would be collected for subsequent analytical 
characterization.  In order to demonstrate the flexibility of the method select model 
proteins: RNaseB, alpha-amlyase and IgG, were subjected to treatment, with results 















5.2 Materials and Reagents  
 
Micro-Liter Syringe Pump (Cole-Palmer) 
Syringes (Thermo-Fisher) 
SDS-PAGE equipment (Bio-Rad) 
Endo-H conjugated silicon wires chip (Provided J.A. Martinez, NMSU Chemical 
Engineering) 
PDMS wet-glue (Provided Z. Gagnon, JHU Chemical Engineering) 
IgG standard 10mg (Pn I2511-10MG, Sigma-Aldrich) 
RNaseB (Provided courtesy of L.X. Wang, UMCP Chemistry & Biochemistry) 
Alpha-Amylase (Provided courtesy of Y.C. Lee, JHU Biology) 
Copper Conductive Tape, Double Sided (Pn 77802-22, Emsdiasum 
Scotch 665 Double Sided, 3/4", no liner (Pn 77102, Emsdiasum 
Endo-H Deglycosidase, 10000 units (Pn P0702S, New England Biolabs) 
 
5.2.1 SDS-PAGE gels 
 
Protein samples were subjected to polyacrylamide gel electrophoresis (Bio-Rad) under 
reducing conditions.  For Coomassie blue staining, the polyacrylamide gel was soaked 
into the staining solution (1% w/v Coomassie blue, 50% v/v methanol, 10% v/v glacial 
acetic acid and 40% v/v of H2O) for 3 h and then transferred the gel to destain solution 
(50% v/v methanol, 10% v/v Glacial acetic acid and 40% v/v of H2O) for overnight 
destaining.  Gels were then imaged using Bio-Rad gel imager. 
 
5.2.2 Liquid chromatography-Mass spectrometry (LC-MS) 
 
The LC-MS was performed on a LXQ system (Thermo Scientific) with a Hypersil GOLD 
column (1.9 μm, 50 × 2.1 mm). The samples were treated with 0.5% beta-
mercaptoethanol and heated at 60 °C for 15 min. then subject to LC-MS measurement. 
The analysis was performed at 60 °C eluting with a linear gradient of 10–40% MeCN 
containing 0.1% formic acid within 10 min. at a flow rate of 0.25 mL/min. Total Ion 
Chromatogram (TIC), Extracted Ion Chromatogram (EIC) and Deconvulated Mass 
Spectrum (DMS) are shown in the results section 5.3.  Performed in the lab of Lai-Xi 



















Figure 28: Initial structure of the glyco-reactor device. 
 
To determine the volume of the reactor housing, the reactor was first weighed dry 
on scale, and subsequently zeroed.  After achieving steady state liquid flow of H2O 
across the reactor, the liquid was stopped, and the reactor was again weighed.  By the 
difference in weight, DI water weighed .1490g, this translated to an approximate volume 
of fluid in the reactor as 0.1490mL, or ~150uL of liquid volume across the surface of the 
reactor.  It was also found that in it’s current configuration the reactor reservoir does not 
fill completely, it merely forms a lake across surface of the chip contained by the PDMS 
housing that flows via the tubing.  This could result in limited fluid mixing, as the device 
is of micro-scale, it would be difficult to install a small propeller or stirrer to keep fluid 
moving around in the chamber to ensure continuous mixing.  Perhaps at higher 
temperatures thermal convection could more rapidly transport analytes within the 
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chamber, however care must be taken to avoid denaturation of the protein and 
evaporation of the sample.  
 
 
Figure 29: Dismantled reactor housing.  
 
Figures 28 and 29 shows what the outside and inside of the reactor housing 
looked like. In this configuration, the device had numerous leaks, no matter what low 
flow rate was used 5-200 µL/min.  The inlet and outlet tubes cause protrusion of the 
PDMS base plan around them resulting in a not flat surface, this irregularity prohibits a 
good seal.   The initial use of double-sided tape does not form a seal capable of 
withstanding the pressure of fluid flow.  So the thought to switch to a thicker tape that 
was also conductive was done.  Double sided copper tape then provided a much thicker 
plane to ease the unevenness of the other part geometries, as copper is malleable it would 
bend to the distortions inherent to the construction of the reactor housing. The base plane 
is a lab-glass slide, which would not conduct current.  The copper tape proved a very 
useful tool to seal the deck of the Endo-H SiNW chip to the glass slide, result is shown in 
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Figure 30.   However, copper tape provided better seal than the plastic tape as it was 




Figure 30: Copper tape seal of Endo-H enzyme SiNW Chip. 
 
Using ‘wet PDMS’ was found the most practical way to seal, however cannot 
incubate in quick bake, or use plasma torch to dry as the surface enzymes will be 
degraded.  So the copper tape with chip sealed inside and then reactor housing top was 
then sealed with wet PDMS.  To avoid the quick bake or plasma torch, a long wait time 
for wet PDMS to fully cure while constantly keeping enzyme surface wet through 
minimal addition of solvent directly onto chip during drying at room temperature in the 
dark, allowed the PDMS to cure and thus seal the reactor housing.  With this 
modification was able to achieve sealed reactor with Chip inside with ZERO LEAKS at 
flow rates up to 50µL/min.  Figure 31 shows the sealed reactor connected to a syringe 





Figure 31: PDMS sealed reactor. This shows the sealed reactor with Endo-H SiNW inside 
connected to a syringe pump delivering protein solution into the chamber. 
 
Although no fluid was no leaking, another issue with the architecture of the 
reactor design arose.  Namely, an issue of head-space above the chip caused by the fluid 
lake formed across it as discussed earlier, resulted in evaporation of the fluid during 
incubation at 37°C within the chamber resulting in no recoverable sample.  Collection of 
the sample was attempted by flushing 150µL of DI H2O across the reactor and then 
removing the fluid in an attempt to resolubilize the protein.  Instead it was found that a 
24-Well plate had sufficient diameter to allow placement of the Endo-H SiNW chip 
within a well, shown in Figure 32.  The appropriate volume of fluid placed above the chip 
was determined to be 300-400µL.  This allowed sealing of the plate with lid attached 




Figure 32: Endo-H SiNW chip in 24-Well Plate. Figure A shows the chip placed in upper 
left corner and immersed in 400µL of H2O.  Figure B shows the plate with lid wrapped in 
parafilm to prevent evaporation. 
 
Now that conditions were optimized to assess the activity of the Endo-H SiNW 
chip, a target protein was attempted.  Alpha-Amylase (MW 51kDa) with one n-glycan 
site with Man5 (MW 1235 Da) was chosen because of it’s unique glycosylation pattern.  
As Endo-H enzyme has limited reactivity towards certain glycoforms, alpha-amylase is a 
high-mannose type glycoform, therefore amenable to digestion by Endo-H.  As a control 
experiment, 1.5µL of Endo-H purchased from NEB, was digested with 5µg of alpha-
amylase in a 37°C oven for 1 hour according to NEB protocol.  The Endo-H SiNW chip 
placed in a 24-well plate was then incubated with 350µL of 0.1mg/mL intact, non-
reduced, non-denatured alpha-amylase in a 37°C oven.  At 4 hours a 25µL aliquot was 
removed for analysis.  Then at 30 hours the plate was removed from the oven, the sample 
removed, however, the sample had evaporated 2/3 of its original volume, resulting in an 
increase of the protein concentration within the sample, this was evident on the gel image 
shown in Figure 29. Figure 29 shows a 15% Polyacrylamide SDS-PAGE gel run in 
reducing conditions as protein has disulfide bonds.  The high acrylamide percentage was 
needed to be able to resolve +/- 1235 Da shift in mass.  The molecular weight of alpha-
amylase is 51kDa and the molecular weight of Endo-H NEB Cat # P0702S is 29kDA.  As 
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Figure 33 shows, he chip’s Endo-H enzyme is catalytically active, 4 hours shows no real 
shift in shift, at 30 hours showing complete population shift to deglycosylated state. 
 
 
Figure 33: SDS-PAGE of Endo-H SiNW chip digest of Alpha-Amylase. 0.7g load of 
protein. 
 
Now that the enzyme chip was found catalytically active another target enzyme 
was chosen.  RNaseB, is a widely used glycoprotein standard, it has high-mannose glycan 
structures from Man5-Man9.  As a control experiment, 5 micrograms of RNaseB was 
digested with 1.5uL Endo-H enzyme in a 37°C oven for 1 hour according to NEB 
protocol.  Previous attempts at using the PDMS sealed glyco reactor all resulted in 
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evaporative loss of the sample, to overcome this, the reactor inlet and outlet tubes were 
sealed with parafilm to try to prevent escape after placement of 150µL of 0.1mg/mL 
intact, non-reduced, non-denatured RNaseB into the reaction chamber, the reactor was 
then placed into in a 37°C oven overnight for 14 hours.  Separately, an Endo-H SiNW 
chip was placed in a cut-out well from a 24-well plate, then 500µL of 0.1mg/mL intact, 
non-reduced, non-denatured RNaseB was added and wrapped in parafilm to prevent 
evaporation and placed in a 37°C oven.  At 19 hours a 50µL aliquot was removed for 
subsequent analysis.  Then at 48 hours the well containing chip was removed from the 
oven.  Even when wrapping the ends of the inlet and outlet tubes of the sealed glyco-
reactor evaporation occurred.  During the RNaseB reactor digest the ~150µL sample 
evaporated during the 37°C incubation, the protein was reconstituted in 150µL of H2O to 
remove and collect the sample for subsequent analysis by SDS-PAGE and mass spec.  
Figure 34 shows a 15% Polyacrylamide SDS-PAGE gel of the samples ran in reducing 
conditions, the high acrylamide percentage was needed to be able to resolve the shift in 




Figure 34: SDS-PAGE gel of RNaseB Reactor Digest. 0.7g load of protein. 
 
In Figure 34, it can be seen that both the glycosylated and deglycosylated forms 
of RNaseB exist in the Endo-H SiNW chip digest at 19 hours.  This indicates a rather 
slow reaction time, due to limited amounts of enzymes on the surface, limited enzyme 
activity and/or limited interaction of the substrate and enzyme due to poor fluid mixing.  
Figure 30 again confirms that the Endo-H SiNW chip is catalytically when compared to 
the Endo-H solution digest control.  At 48 hours showing complete population shift of 
RNaseB to deglycosylated state. 
To prove that the reverse reaction of spontaneous re-glycosylation of the 
deglycosylated RNaseB material was not occurring, the samples were then subjected to 
the time incubation scheme shown in Figure 35.  It can be seen that no shift in molecular 
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weight can be observed for the RNaseB in all cases, thus proving that the deglycosylation 
reaction was not proceeding in the reverse direction.    
 
Figure 35: SDS-PAGE gel of deglycosylated RNaseB Reactor Digest.  0.7g load of 
protein. 
 
To prove absolutely certain that the Endo-H SiNW chip was performing 
deglycosylation, the samples from the RNaseB experiment were subjected to LC-MS.  
Each protein sample was loaded onto the column at 1 µg. 
 
 





Figure 37: DMS for RNaseB Glyco-Reactor at 14 hour digest. 
 
Even though the gel was not able to detect any leftover RNaseB in the evaporated 
Glyco-Reactor digest, the Mass Spec analysis was able to get signal, albeit at low signal 
intensity (Figure 36), nonetheless the data shows that the chip was indeed performing 
deglycosylation prior to drying out.  On the chromatographic conditions used RNaseB 
was found to elute at ~2.2min.  In the EIC of Figures 36 and 37, the B9 fragment ion (m/z 
1656.56) corresponds to Man5 glycoform, with the A8 fragment ion (m/z 1736.29) 
corresponds to Man9 glycoform, the A9 fragment ion (m/z 1543.78) corresponds to 
deglycosylated form of RNaseB.  In the top of Figure of 37, the masses of 13885-, 
14900- and 15062-Da correspond to deglycosylated, Man5 and Man6 glycoforms of 
 92 
RNaseB respectively.  It can be noted that the presence of both intact and deglycosylated 
species in the evaporated glyco-reactor sample, indicates that the reaction probably 








Figure 39: DMS for Intact RNaseB. 
 
In the top of Figure of 39, the masses of 14898-, 15222-, 15385-  and 15062-Da 




Figure 40: TIC and EIC for Endo-H digested RNaseB in solution. 
 
As shown in Figure 40, the RNaseB molecule elutes at ~2.3 minutes and the Endo-H 




Figure 41: DMS for Endo-H digested RNaseB in solution. 
 
As shown in Figure 41, the reaction of RNaseB digested in solution with Endo-H 
achieved complete deglycosylation to the mass of 13884 Da corresponding to the 
RNaseB containing GlcNAc stump.   
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Figure 43: DMS for glyco-chip digestion at 19 hours. 
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As seen in Figure 43, can be seen that both the glycosylated (molecular weights at 15061 
and 15223 Da corresponding to Man5 and Man6) and deglycosylated (molecular weight 
at 13884 Da) glycoforms of RNaseB exist in the Endo-H SiNW chip digest at 19 hours.   
 






Figure 45: DMS for glyco-chip digestion at 48 hours. 
 
In Figure 45, the Endo-H SiNW chip digest of RNaseB at 48 hours shows 
complete deglycosylation to the mass of 13884 Da corresponding to the RNaseB 
containing GlcNAc stump, this weight correlates with the gel image of Figure 34. 
Next IgG was subjected to glyco-chip digestion.  400µL of 0.1 mg/mL IgG were 
incubated with the Endo-H SiNW chip for 48 hours in 37°C incubator.  A separate digest 
by PNGaseF was done to prove that the complex glycans attached to the IgG could be 
removed, 10 micro-grams of IgG were mixed with 1uL of PNGaseF and allowed to 
incubate for 24 hours at 37°C.   As can be seen in Figure 46 SDS-PAGE gel, the 
molecular weight of IgG heavy chain is ~50 kDa, and that of IgG light chain is ~25 kDa.  
The IgG light chains show no variation in molecular weight in all cases because IgG do 
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not typically contain Fab linked glycosylation.   The heavy chain mass stays constant in 
the the intact IgG standard under both reduced and non-reduced conditions, lanes 2-3, 
and in the glyco-chip with the Endo-H enzyme showing no reaction towards complex 
glycans (which is the expected result as Endo-H cannot cleave complex glycans found on 
IgG), lane 5, while in lane 4 the PNGaseF digested IgG resulted in a lower molecular 
weight heavy chain corresponding to the removal of complex glycans of ~1500 Da. 
 
 










Achieving uniform, consistent and specified protein glycosylation in cell 
expression systems remains a case-by-case basis requiring a certain set of 
gene/protein/enzyme expression and activity levels, as well as the spatial availability of 
the nucleotide sugar substrates in the ER and Golgi, involved in glycosylation product 
formation.  To overcome the tedious and inherently expensive cell culture based 
approach towards controlling glycosylation, aim two of this thesis has demonstrated an in 
vitro approach that uncouples glycosylation products from cell, media and process 
conditions.  This approach utilized a cell-free bioreactor to remove glycans from proteins 
generating uniform, structurally defined glycoforms.   
The microfluidic system presented herein was designed to reduce sample volume, 
analysis time and cost.  In this process herein, the enzyme Endoglycosidase-H was 
conjugated to a forest of vertical silicon nano-wires to carry out the deglycosylation 
under physiological buffer conditions leaving the terminal GlcNAc of the chitobiose core 
attached to the asparagine.  However, a major drawback of this enzyme is it’s limited 
and/or no reactivity toward certain hybrid and complex glycoforms, preventing the glyco 
re-modelling of mAb’s (predominantly complex glycoforms G0-,G1-, and G2-F).  Future 
studies should conjugate Endoglycosidase-M or Endoglycosidase-S to be amenable to a 
wider variety of protein substrates.   
The yield of modified glycoproteins is strongly dependent of the surface 
concentration of viable Endo-H enzymes, the rate of the enzymatic reaction, and by 
controlling the extent of the reverse reaction.  Future efforts should determine the 
concentration of conjugated Endo-H enzyme to the silicon nanowires.  Due to bound 
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enzyme on a very small surface area, long reaction times are required to compensate. 
Currently operated in batch mode but larger surface area could allow for continuous 
mode operation.  
The device is “short-circuited” meaning it is currently grounded on itself.  Resistance is 
measured across an object; need to measure voltage between two electrode plates, not on 
the same one. 
The surface area on the enzyme chip available is too small for any high-
throughput application.  However, it is envisioined that upon scale-up of this reactor 
configuration, continuous mode operation could be achieved where-in it would become 
an additional unit operation within bio-process laboratories.  The glycosidase “Endo-H” 
is not reactive towards complex glycans and shows limited toward hybrid glycan 
structures. This was demonstrated not to work with IgG whose predominant glycoform is 
complex.  Though more expensive; Endo-S, Endo-A or Endo-M glycosidase enzymes 
may be better enzymes to conjugate going forward to allow wider access for different 
protein glycoforms.  It is critical that these glycosidase leave the terminal GlcNAc stump 
attached to the asparagine or it will not be compatible with LX Wang’s trans-
glycosylation machinery.  
Future steps for this process would be to acquire the transglycosidases and 
oxazoline substrates (Wang, 2014) then used for en bloc transfer of desired glycoforms 
back onto the deglycosylated protein.  In this way, in principle, any specific and desired 
glycoform can then be incorporated onto a protein.  The improved efficiency and 
flexibility in making various glycans would facilitate glycoform specific use in research, 
clinical and industrial applications. 
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Conclusions and Future Work 
 
 A new paradigm in the manufacturing process issued by the main regulatory 
bodies such as the United States Food and Drug Administration (USFDA) and European 
Medicines Agency (EMEA), encourage the implementation of Quality by Design (Qbd) 
into the manufacturing process.  The tenets of QbD are the development and manufacture 
of pharmaceutical products through well-understood processes to ensure consistent, 
predefined quality at the end of the manufacturing process, therefore facilitating reduced 
approval times and increased flexibility towards changes in manufacturing process 
conditions.  This is accomplished by defining the desired product performance, 
identifying critical product attributes and the parameters that affect those product 
attributes, and timely measurements of those attributes to achieve the defined product 
performance.  This requires definition of acceptance limits, and the eventual testing of the 
product’s quality throughout production for validation of such specified process 
parameter ranges.  Glycosylation is a main source of product heterogeneity in 
biotherapeutics (Del Val, 2010) serving essential functions of the biotherapeutic (Spahn, 
2014), and thus is a critical protein quality attribute to consider its biogenesis during the 
biopharmaceutical manufacturing process.  Once the biotherapeutic (protein) and its 
desired glycosylation pattern with associated efficacy are set, the QbD methodology 
synergizes how the manufacturing conditions give rise to the desired product profile with 
built-in analytical tests to ensure a self-correcting mechanism of action towards those 
specified product attributes.  Thus by applying a DoE approach (e.g., factorial design) 
streamlines the investigation of the impact of muti-factors, muti-variables, and their 
interactions on N-glycosylation.  Towards this goal, Thesis Objective One entailed 
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developing a toolset to provide inputs to defining such acceptable criteria during the 
manufacturing campaign, through HPLC-based methods to determine the amino acid 
composition, glycosylation patterns, nucleotide sugar distributions and titer.  As amino 
acids are substrates for nucleotides, which are components of nucleotide sugars, which 
are the substrates for glycosylation on the synthesized protein, which determines the 
glycosylation pattern, these assays synergize how the glycosylation profile is inextricably 
linked to substrate availability, enzyme activities and cellular metabolism.  Thus 
providing a systematic framework to facilitate the exploration and screening of process 
conditions, media compositions, and cell lines that command desired glycosylation of the 
biotherapeutic.  Furthermore, this framework can be used to track the cellular status 
during production steps for monitoring conditions as added quality control measures to 
prove the production run falls within set specifications.  Such identification of “bad 
batches” would allow early termination of runs not in specification and thereby prevent 
prolonged and expensive continuation of doomed cultures.  It is envisioned that this could 
become a novel analytical toolset in Chemistry Manufacturing and Control data sections 
to support increased knowledge of process conditions and ways to ensure that the product 
is controlled within specified quality criteria throughout production.  Principally this 
method could be used to identify bottle necks in cellular metabolism and glycosylation, 
and consequently engineering strategies to overcome them. In medical application, the 
metabolic phenotypes of healthy and diseased cells are not homogeneous, but instead 
depend strongly on the molecular alterations and environmental factors at play in each 
case. Thus the hope in applying such technology to different cell types (or in principle, 
any cell type) will be to identify cell type specific metabolic signature’s that are 
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characteristic of each type. Especially intriguing is the elucidation of key metabolic 
regulatory check points based on changes in the intracellular processing events and 
enzyme activities, thereby increasing our understanding of the cellular mechanisms that 
have gone awry in healthy and diseased states.  As an example, in many diseased states, 
including cancer, the distributions of glycan structures often differs from that of healthy 
cells, leading to the possibility that such disease-specific glycan phenotypes exist and that 
these differences can be exploited for thera-nostic purposes in the identification of 
disease-associated biomarkers and design of bioengineered glycan modifications.  
Additionally, measurement of these key glycosylation parameters can then serve as inputs 
to computational model-based investigations. A current challenge is to interrelate the 
different levels of available information, from the genome to the transcriptome to the 
proteome to the metabolome to the glycome, and how this experimental data can be 
modeled to recreate a given phenotype and ultimately make predictions about network 
topology and cellular behavior.  Such predictions would facilitate more cost effective and 
faster alternatives to costly screening strategies, thereby reducing the experimental design 
space required to direct the glycosylation pattern.  These systems-level analyses of 
glycosylation encompassing both experimental and computational data will elucidate 
deeper insights into the mechanisms underlying and controlling glycosylation.  
Achieving uniform, consistent and specified protein glycosylation in cell 
expression systems remains a case-by-case basis requiring a certain set of 
gene/protein/enzyme expression and activity levels, as well as the spatial availability of 
the nucleotide sugar substrates in the ER and Golgi, involved in glycosylation product 
formation.  To overcome the tedious and inherently expensive cell culture based 
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approach towards controlling glycosylation, aim two of this thesis has demonstrated an in 
vitro approach that uncouples glycosylation products from cell, media and process 
conditions.  This approach utilized a cell-free bioreactor to remove glycans from proteins 
generating homogeneous glycoforms.  In this process, the enzyme Endoglycosidase-H 
was conjugated to a forest of vertical silicon nano-wires to carry out the deglycosylation 
under physiological buffer conditions, leaving the terminal GlcNAc of the chitobiose core 
attached to the asparagine.  However, a major drawback of this enzyme is it’s limited 
and/or no reactivity toward certain hybrid and complex glycoforms, preventing the glyco 
re-modelling of mAb’s (predominantly complex glycoforms G0-,G1-, and G2-F).  Future 
studies should conjugate Endoglycosidase-H or Endoglycosidase-S to be amenable to a 
wider variety of protein substrates.  Future steps for this process would be to acquire the 
transglycosidases and oxazoline substrates then used for en bloc transfer of desired 
glycoforms back onto the deglycosylated protein.  In this way, in principle, any specific 
and desired glycoform can then be incorporated onto a protein, thereby facilitating 














Cell counts were performed using a hemocytometer and a light microscope.  After 
removing cells from the plate, a small aliquot was taken for cell counts.  50 uL cell/PBS 
mix was mixed with 750L tryphan blue (Cellgro, Manassa, VO).  10 uL of this mixture 
was added to each side of the hemocytometer and stained cells were counted.  Each count 
was repeated at least two times.     
 
Treatment of Cultures With 1,3,4- O-Bu3ManNAc and ManNAc 
 
CHO-K1 cells were seeded at 1x10^6cells in 10 cm dishes in10 ml Ham’s F-12K media 
untreated or treated with 20 mM ManNAc (Sigma–Aldrich) or various concentrations of 
1,3,4-O-Bu3ManNAc (50, 100, 150, 200, 250, 300, 350 µM). Cells were collected at 
confluency at over 90% after 3 days.  Supernatants were collected after 48 h incubation 
with or without treatment and then subjected to IgG purification. 
 
Protein-A IgG Affinity Chromatography to Assess mAb Titer 
 
HPLC: Shimadzu LC-10Ai 
Column: TSKgel Protein A-5PW, 20 µm, 4.6 mm ID × 3.5 cm 
MPA: 20mM NaPO4 pH 7.20 
MPB: 100mM NaPO4 pH 3.00 
Detector: U.V. Abs. 254 and 280nm 
Flow Rate: 1 mL/min 
Step-Gradient: T0 = 0%B, T3.20 = 100%B, T6 = %100B, T6.01 = 0%B, T10 = 0%B. 
Injection Volume: 10µL 
Sample Preparation: Cell media containing IgG filtered through 0.22µm syringe-filter. 
 
 
Figure 47: Protein-A HPLC Chromatogram. 
Human-IgG Std: Orange 1mg/mL, Blue .5mg/mL. Media Sample at 





Figure 48: Protein-A Chromatography IgG Calibration Curve. The cell 
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- Fostered a collaboration with Anne Le, MD/PhD, Johns Hopkins Pathology; 
Metabolomic studies of human cell lines (PANC,P493) using stable isotopically labelled 
cell media feeds incorporating 13C-Glucose or 13C,15N-Glutamine for correlating 
metabolite differences with biochemical relationships in metabolic pathways, developed 
LC-MS/MS methodologies using Agilent 1290 LC with 6550 Q-ToF MS and 6490 QQQ 
MS for identifying and quantifying various bio-molecules using Agilent’s MassHunter 
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the theory and practice of LC utilizing Agilent Infinity 1260 LC 
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cells, cell counting (Beckman Coulter cell counter and hemocytometer), cell lysis and 
metabolite extraction, performed on cell lines: CHOZN GS, CHO K1, PANC, and P493 
- Microfluidic device: Construction of a micro-reactor using PDMS housing for in-
vitro glycosylation using solid phase enzyme catalysis (Endo-H) on etched silicon 
nanowires to produce homogenous glycoforms of proteins: Alpha-Amylase, RNAseB, 
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-  Temporary job to serve for stipend assistance in paying for school, resigned for 
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-  Intermediate level of mass spectrometry analysis (Waters Xevo QToF, Thermo LTQ 
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-  Sub-Visible Particle Analytical Techniques: Nanoparticle Tracking Analysis 
(Nanosight NS500) for nanometer range and MFI (Protein Simple 5200) for micrometer 
range   
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Dualtec) in conjunction with Static Multi Angle Light Scattering (MALS) (Wyatt Optilab 
T-rEX and miniDAWN TREOS) and Dynamic MALS (Wyatt DynaPro Plate Reader II) 
for measuring protein aggregation, oligomeric state, hydrodynamic radii and protein 
conjugate analysis (PEGylation and glycosylation)  
-  Carry out long-term protein stability studies by forced thermal, mechanical (sheer 
stress), pH (acidic and basic), oxidative, formulation selection, and freeze/thaw cycling   
-  Post-translational protein modification studies: iso-aspartate isomerism and free 
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  -  Determination, quantitation, and identification of process-related impurities 
  -  Determination of solution protein concentration (A280) using Nanodrop, Jasco, and 
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-  Electrophoretic techniques: SDS-PAGE, Native PAGE, Isoelectric Focusing (IEF 
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-  Glycobiology: N-linked glycan analysis, O-linked glycan analysis, sialic acid 
content and total monosaccharide analysis   
   -  Tracking, processing, maintaining and ordering chemical and sample inventory  
   -  Responsible for shipping and receiving of incoming and outgoing materials 
   -  Unofficially named the department IT support; excellent computer and 
programming skills for troubleshooting PC-related problems   
   -  Report findings to superiors in a timely and efficient manner 
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Baxter Bioscience, Glendale, CA, Technical Services Department, Process 
Development Group, Research Associate 
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Reported to Vladamir Shlimak, D.Sci. and Irene Ch’en, Ph.D.  
-  Hired to work as a process engineer for the FDA submission of process changes to 
the Baxter AHF-M process to demonstrate process comparability  
-  Glendale Baxter plant is World's largest and most advanced human blood plasma-
fractionation protein production facility  
-  Responsible for process steps from thawing of frozen blood plasma to viral 
reduction/inactivation to plasma component separation to affinity chromatography to 
nanofiltration  
  -  Wrote the programs and operations for automating all process steps onto GE AKTA 
series FLPC  
-  Sole author of departments SOP on instrument description, calibration, operation 
and maintenance  
-  Conducted laboratory bench and pilot plant scale protein purification and 
separation studies, including sample collection, sample preparation, and sample 
submission  
   -  Used sophisticated laboratory instrumentation and computer systems to collect and 
record data   
   -  Hands-on operation, set-up, cleaning, and sanitization of bioreactors and lab 
equipment  
 
-  Performed and developed advanced biochemical assays requiring precise analytical 
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skills and understanding of biology and chemical principles: ELISA, Western Blot & UV-
Vis  
 
-  Completed all testing and analyses of experimental materials in a timely and 
appropriate manner  
 
-  Prepared study protocols/final reports, maintained data integrity, and ensured 
compliance with company SOPs, GLP and cGMP regulations   
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pilot scale studies and production  
 
-  Prepared buffers and solutions, performed equipment maintenance and calibrations 
as required: pipettes, pH, Conductivity & pressure monitors  
 
-  Worked as a ‘runner’ of documents requiring authorization by all departments of 
quality assurance, biochemistry, quality control, engineering, validation, regulatory, and 
technical services helping to expedite document change revisions for inter-departmental 
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Reported to Daniel DeMartini, Ph.D.  
-  Elucidation of Physico-Biochemical Mechanism of Adaptive Squid Bio-
Luminescence in Cephalopod Iridophore tissue via a Bragg Reflector Optical Construction 
Mechanism -Preparing solutions and buffers, carrying out assigned experiments, analyzing 
data, implementing subsequent research objectives, recording all duties performed & data 
obtained in lab and presenting findings in weekly interdisciplinary group discussions  
 
-  PCR, Protein expression in E. Coli, Extensive protein purification using 
HPLC/FPLC (Fisher Bioscience): IEX & HIC, spin columns, SDS-PAGE and Western 
Blot, ELISA, lyophilization, TEM & SEM (cell imaging), Zeta-Potential (hydrodynamic 
radius), MALDI-ToF Mass Spectrometry (the kind you drive with a joystick), 
determination of protein refractive indices (custom construction of a micro-volume 
interferometer Snell’s Law), Circular Dichroism (secondary structure), sterile filtration 
techniques, filling syringes and vials, fume hood work, studying protein cross-linkage and 
post-translational modifications, mapping neural molecular pathways through enzyme 
inhibition and activation using neurotransmitters and small molecules, dissection skills: 
tweezers and scalpel under microscope for tissue excision and isolation  
 
M. Scott Shell Lab, Bio-Physics & Condensed Matter Group, Department of 
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March 2009 - Jun 2010  
-Computer simulations to probe protein folding pathway energy landscapes and 
conformational spaces using Molecular Mechanics 
 
- Helped to develop protein docking simulations using free energy minimization 
calculations -Developed algorithms to probe molecular interaction theories using AMBER 
force field parameters 
 




-Record all duties performed & data obtained in lab notebook, analyzed data and presented 
findings in weekly group discussions 
 
In-N-Out Burger Inc., Part-Time Manager 
February 2004 - August 2008  
-Responsible for general overall supervision of store; maintaining inventory, employee 
schedules and ensuring company guidelines and policies were followed 
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UCSB Materials Research Laboratory, CAMP Intern, 2010-2011  
Selected candidates conduct work in a UCSB laboratory focusing on materials science and 
engineering research, participate in weekly group meetings, attend special seminars and present 
their results at an end-of-quarter poster sessions 
 




Cycling, cooking, design: art & architecture, cars (motorsport) and surfing 
